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ABSTRACT 
Epidemiological data and studies in rodent models strongly support the role of 
estrogens in the development of breast cancers. Estrogens have been added to the list of 
known human carcinogens. Exact mechanisms underlying the initiation and progression 
of estrogen-related cancers are not clear. Literature evidence and our studies strongly 
support the role of estrogen metabolism mediated oxidative stress in estrogen-induced 
breast carcinogenesis. It was recently demonstrated from our laboratory that antioxidants 
vitamin C or butylated hydroxyanisole (BHA) strongly inhibit 17β-estradiol (E2)-induced 
breast tumor development in female ACI rats. The objective of present study was to 
characterize the role of CNC b-zip transcription factors in antioxidant-mediated 
prevention of breast cancer. 
The present study was based on the central hypothesis that 17β-estradiol mediates 
carcinogenic insult in the cellular environment by producing reactive oxygen species 
(ROS) / oxidative stress during its metabolism to quinones. This oxidative stress can be 
controlled by production of phase-II detoxifying antioxidant enzymes. In order to test this 
hypothesis we examined the cellular levels of different antioxidant enzymes after 
treatment with E2. We then investigated the molecular mechanism(s) and pathways 
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involved in E2-induced breast carcinogenesis. To address the question if antioxidant 
agents can reverse E2-induced oxidative stress and ultimately mediate chemoprevention 
of breast cancer, we checked several different cellular antioxidant enzymes’ levels and 
dissected out possible molecular pathways involved after treatment with naturally 
occurring well studied antioxidants like resveratrol (Res), resveratrol analogs (TIMBD 
and HPIMBD) and Vitamin C.  
Resveratrol has been shown to reduce primary tumor growth of xenografts in a 
nude mouse model. But its clinical applications in prevention of breast cancer are limited 
because of its lower efficacy in in vivo systems. Thus, to improve the anticancer and 
antioxidant efficacy of Res and to use it as a successful agent targeting breast cancer, 
pharmacologically active resveratrol analogs have been synthesized. Our newly 
synthesized Res-analog compounds: 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol} 
(TIMBD) and 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1, 2-diol} (HPIMBD), 
have effectively inhibited the growth of breast cancer cells and have no/minimal 
cytotoxicity towards normal cells. To further delineate the mechanisms responsible for 
higher growth inhibitory potency of TIMBD and HPIMBD, we have aimed at finding out 
its antioxidant potentials. In this current work we have shown the contribution of TIMBD 
and HPIMBD in providing antioxidant defense in human breast epithelial cells. In our 
previous studies we have shown that estrogen-induced breast carcinogenesis is initiated 
by down-regulation of expression of the antioxidant enzymes, superoxide dismutase 3 
(SOD3, also known as extracellular superoxide dismutase) and NAD(P)H:Quinone 
Oxidoreductase 1  (NQO1), via a nuclear factor erythroid 2-related factor 2 (Nrf2)-
dependent signaling pathway. In this present study, we have shown that a new and potent 
v 
 
resveratrol analogs TIMBD and  HPIMBD, synthesized by our collaborating team 
functions to inhibit E2-dependent breast cancer development by up-regulation of the 
expression of SOD3 and NQO1 via this same Nrf2-dependent pathway.  We have also 
provided evidence how TIMBD and HPIMBD mediate antioxidant defense through 
regulation of CNC-bzip transcription factors other than Nrf2; nuclear factor erythroid 2-
related factor 1 (Nrf1) and nuclear factor erythroid 2-related factor 3 (Nrf3). 
We also investigated the potential roles of Res-analogs in prevention of epithelial-
mesenchymal transition (EMT). An epithelial-mesenchymal transition can be defined as a 
biological process which mediates a phenotypical change in the polarized epithelial cells 
to mesenchymal cells. Epithelial cells, which interact with basement membrane, undergo 
different complex biochemical and molecular changes to become mesenchymal cells. The 
process of EMT increases a cell’s migratory and invasive properties. It is well 
documented that the process of EMT plays a very critical role in cancer metastasis. The 
effects of Res-analogs on EMT and the migration of human breast cancer cell lines were 
studied. We found that Res-analogs significantly increased epithelial marker E-cadherin 
expression and down-regulated matrix metalloproteases (MMPs) and expression of 
mesenchymal markers, such as snail, slug, zeb1/2. In present studies, we have 
demonstrated the potential of Res-analogs in prevention of EMT these studies suggest 
that our novel Res-analogs may have the potential to be therapeutic agents for breast 
cancer chemoprevention.  In order to dissect out the possible molecular mechanism of 
Res-analogs on the suppression of EMT and breast cancer cell metastasis, we found a 
critical involvement of β-catenin. The expression and nuclear translocation of β-catenin 
vi 
 
was significantly down-regulated with Res-analogs implicating that these analogs may 
prevent breast cancer cell metastasis involving β-catenin pathway.  
We have also tested the ability of these Res-analogs to inhibit the proliferation of 
5 breast cancer cell lines and 3 non-neoplastic breast epithelial cell lines and compared 
their inhibition potential with Res. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay for cell proliferation  was carried out in human breast cancer and 
non-neoplastic breast epithelial cell lines. The breast cancer cell lines tested were MCF-7, 
T47D, MDA-MB-231, MDA-MB-468 and BT-20. The non-neoplastic breast cell lines 
tested were MCF-10A, MCF-10F and HMEC. Of all the analogs tested, two analogs, 4-
hydroxyphenyl-immino-methylbenzene-1,2-diol (HPIMBD) and TIMBD showed higher 
potency for inhibiting the proliferation of breast cancer cells compared to Res. 
Furthermore, TIMBD or HPIMBD showed higher potency for inhibiting the growth of 
triple negative breast cancer cells (MDA-MB-231, MDA-MB-468 and BT-20) compared 
to estrogen receptor positive breast cancer cells MCF-7 and T47D. There was neither 
inhibition nor proliferation by TIMBD or HPIMBD of non-neoplastic breast epithelial 
celllines. TIMBD and HPIMBD induced Beclin-1 and LC3-II which suggest autophagy 
mediated inhibition of cell growth. Beclin-1 is known to be suppressed in breast cancers 
and it’s over expression is reported to inhibit breast cancer. Results from our studies 
demonstrate that Res-analogs TIMBD and HPIMBD are better than Res in inhibiting 
specifically breast cancer cell growth and shows higher potency for inhibiting the growth 
of triple negative breast cancer cells by inducing autophagy with an earlier onset 
for triple negative breast cancer cells. Therefore, TIMBD and HPIMBD may be better 
chemotherapeutic agents than Res against breast cancer and more specifically 
vii 
 
against triple negative breast cancer cell growth, a cancer type prevalent in 
minority African American population with poor prognosis.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
 
1.1.  Breast Cancer 
Cancer is a group of diseases that is caused due to uncontrolled division and 
growth of cells in the body. The cells of the body which lose the control over cell-
division and growth, due to gene-mutations, become immortal and are called as cancer 
cells. It is very common property of cancer cells to form an aggregated mass of cells or 
lump which is defined as tumor. Breast cancer (Figure 1) is a malignant tumor that 
originates in the breast tissue. If not diagnosed at the early stages, these malignant cancer 
cells can invade the breast tissue and spread to different other tissues of the body, 
resulting in deadly consequences of life-threatening metastatic breast cancer. Breast 
cancer is a disease which occurs mostly in women, but is not limited to; men can also get 
this disease.  
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Figure 1 : Breast cancer 
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The female breast tissue is made up of milk-producing glands or lobules, small 
tubes or ducts that carry the milk produced in the lobules to the nipple, and fatty, 
connective and lymphatic tissue which is defined as stroma.  The ducts and lobules 
remain surrounded by the stroma. Most frequently occurring breast cancer is ductal 
carcinoma which begins in the cells lining the milk ducts. The other type of breast cancer 
which is found in a small number begins in the milk glands or lobules, called as lobular 
carcinoma.  
1.2.  Types of Breast Cancer  
Breast cancer can be of several types based on the tissue of origin (ductal or 
lobular) or based on the nature of the cancer cells, whether they form the malignant lump 
at only one site or spreads in surrounding other tissues of the body (in situ or invasive, 
respectively). But, there can be occurrence of such cases where breast cancer can be a 
combination of different types. The frequently occurring breast cancer types include 
Ductal carcinoma in situ (DCIS), Invasive ductal carcinoma, Invasive lobular carcinoma 
(ILC). Although Lobular carcinoma in situ (LCIS) exists, it is not considered as truly 
malignant type, but considered as a risk factor that can develop into invasive breast 
cancer. The less frequently occurring breast cancers are inflammatory breast cancer and 
triple-negative breast cancer. For the convenience of breast cancer prognosis and 
treatment, specific biological markers have been identified. Based on these molecular 
markers or hormone receptor status on cell surface breast cancer can be classified as 
 estrogen receptor (ER) positive (ER+) or ER negative (ER-),  progesterone receptor (PR) 
positive (PR+) or PR negative (PR-), and HER2/neu positive (HER2+) or HER2 negative 
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(HER2-). Cells with none of these receptors are called basal-like or triple negative breast 
cancer (TNBC). 
 
1.3.  Signs and Symptoms of Breast Cancer 
There are no typical symptoms of breast cancer when the tumor is small and can 
be cured easily. For that reason, it is of utmost importance for women to follow 
guidelines of breast cancer screening for its detection at an early stage. But as a result of 
ignorance and negligence when breast tumor grows to a palpable size, it clearly looks like 
a lumpy mass which does not produce any pain. At times breast cancer can cause 
swelling of lymph nodes under the arm by spreading into it. The less common symptoms 
of breast cancer are pain in the breast tissue, visible changes of the colour and texture of 
the breast skin, swelling, puckering or redness of the breast’s skin, discharge from the 
nipple etc.  
1.4.  Risk factors of Breast Cancer  
Risk factors that affect the chance of getting breast cancer in women include age, 
genetic risk factors, family history, personal history, race and ethnicity, dense breast 
tissue, menstrual periods, late pregnancy, oral contraceptives, environmental chemicals, 
smoking, drinking alcohol, obesity, diet, hormone (estrogen) therapy after menopause 
etc. 
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1.5.  Endogenous Hormone Estrogen Levels as a Risk Factor in Breast Cancer 
Women with higher levels of natural female sex hormone 17β-estradiol (estrogen) 
in their circulation are associated with increasing the risk of breast cancer almost twice 
compared to women with lower levels of estrogen. Not only estrogen, but a higher level 
of testosterone hormone also increases the risk of breast cancer, particularly in 
premenopausal women. So, it should be taken in consideration that besides 
environmental factors, we have our own bodily substances like hormones which play 
critical role as major risk factors for development of breast cancer.  
1.6.  Breast Cancer: The Major Health Problem among US Women 
The number of breast cancer survivors has increased as a result of an early 
detection of the disease and improved treatments. But breast cancer is still the leading 
cause of death occurring from cancer among women in the United States (1-3). 
According to the epidemiological data provided by the American Cancer Society and the 
National Cancer Institute, approximately 14.5 million people are living with cancer on 
January 1, 2014 in the United States. It is also estimated that by January 1, 2024, 
approximately 19 million Americans will be diagnosed with cancer. The most prevalent 
cancers found among male cancer survivors are prostate cancer (43%), 
colorectal cancer (9%), and melanoma (8%). The most common cancer types found 
among females cancer survivors are breast cancer (41%), uterine cancer (8%), colon and 
rectum (8%) (Cancer Treatment & Survivorship Facts & Figures 2014-2015). Breast 
cancer is a devastating disease among women in the United States and worldwide. It is 
still the most important health problem among women in the United States. It is estimated 
as of January1, 2014, approximately 3.1 million women are living in the United States 
with this disease (Cancer Treatment & Survivorship Facts & Figures 2014-2015). 
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According to Cancer statistics data 2014, roughly 232,670 new cases will be diagnosed 
with breast cancer and it is also estimated that approximately 40,000 deaths will occur 
from breast cancer among American women (Figure 2).  
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Figure 2: Ten leading cancer types for the estimated new cancer cases and deaths by sex. A total of 
1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 
2014 (Source: Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA: a cancer journal 
for clinicians) 
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1.7.  Estrogen: A Carcinogen 
Long term exposure to estrogens has been associated with development of breast 
cancer (4-19). Estrogens are now enlisted as chemical carcinogens by the United States 
government (20-22). Chemical carcinogens function by their electrophilicity. Most of the 
chemical carcinogens (95%) need to undergo metabolic activation to give rise to reactive 
electrophilic forms that can react covalently with the nucleophilic groups of DNA, RNA 
and protein (23-26). The other 5% of the chemical carcinogens are direct electrophilic 
alkylating agents that do not need metabolic activation. Thus the chemical carcinogens 
are capable of react readily with DNA molecules, resulting in stable mutations that 
ultimately lead to cancer initiation. 
1.7.1.  Molecular mechanisms of estrogen carcinogenesis 
Two schools of thought exist to explain carcinogenicity of estrogens. One is 
hormone receptor-dependent pathway and the other is hormone receptor-independent 
pathway. In the hormone receptor-dependant mechanism, estrogens bind to the estrogen 
receptor (ER), activate various cellular signaling pathways leading towards cell 
proliferation (27-33), cancer promotion and progression. Although the hormonal 
mechanism explains cell proliferation, it cannot explain the event of cancer initiation 
which is critically dependant on genetic mutation to happen. In the hormone receptor-
independent / metabolic mechanism, estrogens undergo redox reaction during its 
metabolism producing reactive oxygen species (ROS) that can produce irreversible 
mutations and also genotoxic estrogen metabolite–DNA adducts, resulting in cancer 
initiation (4-18, 34). The discovery that specific oxidative metabolites of estrogens, 
catechol estrogen quinones, react with DNA led to and supports the hypothesis that 
9 
 
estrogens can become endogenous chemical carcinogens by generating the mutations 
leading to the initiation of cancer (34-37). 
1.7.2.   Estrogen-induced Breast Cancer: Implication of oxidative stress 
In the breast tissue, 17β-estradiol (E2) can be metabolized by specific cytochrome 
P450 (Cyp) enzymes to catechol estrogens. Two different catechols are produced. 
Metabolism of E2 by Cyp1A1 gives rise to 2-hydroxyestradiol (2-OHE2) and metabolism 
by Cyp1B1 gives rise to 4-hydroxyestradiol (4-OHE2). Among these two products, 2-
OHE2 is not genotoxic but 4-OHE2 is highly carcinogenic. Genotoxic 4-OHE2 can further 
undergo oxidative metabolism and produces semi-quinones and highly reactive quinones. 
These quinones are highly reactive electrophiles having the ability to readily react with 
DNA forming depurinating quinone-DNA adducts. During the process of redox cycling 
between catechol estrogens and E2-quinones, reactive oxygen species (ROS) are 
generated. The oxidative stress that is thus generated during E2 metabolism can damage 
DNA, RNA, lipid and protein molecules leading to DNA mutation and other cellular 
damages and ultimately can cause carcinogenic insult to the cells (Figure 3).   
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Figure 3: Possible molecular mechanism of E2-induced breast cancer: Role of oxidative stress 
(Source: Bhat, HK, Oxidative Stress and Disease, 2006) 
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1.7.3.  Antioxidants in chemoprevention of E2-induced Breast Cancer 
Antioxidant can be defined as a molecule capable of inhibition of oxidation of 
other molecules. Antioxidants can remove free radical intermediates which are generated 
during oxidation reactions. Antioxidants thus protect cells against free-radical induced 
toxicity. Antioxidants are widely used in dietary supplements and have been extensively 
studied for the prevention of cancer and other diseases. Our laboratory has examined the 
role of prototypic antioxidants vitamin C (VC) (13) and butylated hydroxyanisole (BHA) 
in E2-induced mammary carcinogenesis (18).  Vitamin C is one of the most well known 
natural antioxidant found in a variety of fruits and vegetables. It has also been used as a 
dietary supplement in prevention of cancer, cardiovascular and other chronic diseases. 
Butylated hydroxyanisole is another well studied antioxidant agent extensively used in 
food additives in order to protect against chemical carcinogens. The anticarcinogenic 
activity of BHA is attributed to its ability to scavenge free radicals and to induce phase II 
detoxifying enzymes. In previous studies, our laboratory has shown that antioxidants VC 
and BHA significantly inhibit E2-induced breast cancer in animal model of breast 
carcinogenesis, female ACI rats.  Antioxidant agents are suggested to reduce breast 
cancer most likely through induction of antioxidant enzymes or phase II detoxifying 
enzymes. NAD(P)H-Quinone oxidoreductase 1 (NQO1) is a key antioxidant enzyme 
involved in defense against reactive oxygen species and protect against carcinogenic 
insult.  NQO1 converts E2-quinones back to E2-catechols, thus making E2-quinones 
unavailable for reaction with DNA and oxidative stress. The role of NQO1 in prevention 
of E2-induced breast carcinogenesis has been well studied by our laboratory in an ACI rat 
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model of breast cancer (36). During metabolism of estrogen, one electron oxidation of 
catechol estrogens to estrogen quinones take place and superoxide radicals are produced 
as a result of this redox reacation. These superoxide radicals can get converted to 
hydrogen peroxide in presence of sufficient superoxide dismutase (SOD) enzymes. 
Hydrogen peroxide is subsequently removed by cellular catalases and peroxidases. The 
SODs represent the major cellular defense system against superoxide radicals. In 
mammalian tissue, three isoforms of SODs have been identified: the cytoplasmic 
CuZnSOD (SOD1), the mitochondrial MnSOD (SOD2) and the extracellular SOD (EC-
SOD or SOD3). Among all SODs, isozyme SOD3 is currently the least studied in relation 
to hormonal cancer prevention, although recent data support a potentially important role 
for SOD3 in maintaining oxidative homeostasis in the extracellular matrix, as well as in 
the nucleus (38-43). Disruption of the SOD3 gene in mice has been shown to increase 
their level of sensitivity to environmental stressors (39, 44, 45). Normal mRNA and 
protein expression levels of SOD3 are relatively low in human lung and breast cancers, as 
well as in animal models of E2-induced breast cancer (46-48). However, there are 
relatively few, if any, published reports demonstrating the targeting of SOD3 in 
prevention of estrogen-dependent breast cancer other than our recently published finding 
(49). SOD3 is the only member of the SOD family found to date to be suppressed in E2-
induced BCs (49). In this study our laboratory has demonstrated the effects of 
antioxidants VC and BHA on SOD3 expression and role of SOD3 in prevention of E2-
induced oxidative DNA damage and breast carcinogenesis. The effects of antioxidants on 
DNA repair capacity of the cells were very recently explored by our group. 
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1.8.  Phytoestrogens in Chemoprevention of Breast Cancer 
According to epidemiologic observations, the incidence of breast cancer is lower 
in Asian women, who consume significantly higher amounts of phytoestrogens than those 
of westerners (50). Second- and third-generation descendants of women who migrated to 
Western countries from Asia have breast cancer risks similar to those of women in the 
host country, suggesting that lifestyle and not genetic factors explain the low breast 
cancer risk observed in Asian women (51). However, in spite of recent awareness related 
to the known chemopreventive properties of phytoestrogens, epidemiologic studies have 
produced inconsistent results, and the relationship between phytoestrogens and breast 
cancer remains controversial (52, 53). Moreover, the possible mechanisms of 
phytoestrogen action in breast cancer have yet to be resolved. Phytochemicals can be 
categorized into different groups such as chlorophylls, phytosterols, carotenoids, 
isothiocyanates, phytoestrogens etc (54). Phytoestrogens are one group of nonessential 
plant chemicals or phytochemicals that have been suggested to play important role in 
cancer prevention (54-59). Phytoestrogens are bioactive compounds, similar in structure 
to endogenous estrogens (60, 61). It is evident from literature that higher consumption of 
phytochemical-rich diets can reduce risk of cancer in both in vivo and in vitro studies (62-
64). Although thousands of different varieties of phytochemicals have been identified, 
it’s still challenging to study millions of more undiscovered plant chemicals and 
understand their modes of actions. Phytoestrogens are found in various fruits and 
vegetables, nuts, soy beans and soy products, flaxseeds, dark chocolate, red grapes and 
red wine (54, 57). Phytoestrogens exert Estrogenic and/or antiestrogenic properties and 
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various other biological properties (Figure 4) like antioxidant, antiangiogenic, 
antiproliferative etc (59, 65-71). It has been studied that postmenopausal breast cancer 
risk can be reduced following increased consumption of phytoestrogens in the subjects 
who were without hormone replacement therapy (72). 
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Figure 4: Different potential mechanism of actions of phytoestrogens 
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1.8.1. Resveratrol and Breast Cancer Prevention 
Resveratrol (Res) (3,5,4’-trihydroxystilbene) is a naturally occurring polyphenolic 
compound  from stilbene family (73-76). Resveratrol is considered as a phytoestrogen as 
it is an estrogen like compound present in plants; it has got structural similarity with the 
estrogenic compound diethylstilbestrol (77-79). It is found in various plant products 
grapes, peanuts, berries, Polygonum roots etc (80-83). It can be found as cis- or trans- 
stereo-isomeric forms (84-86). It was first discovered by Michio Takaoka more than 60 
years ago, in the resin of Veratum grandiflorum (false hellebore) (87). Thereafter, Res 
was also detected in grapevines (Vitis vinifera) in 1977 by Langcake, who found that the 
compound was synthesized by leaf tissues in response to fungal infection or exposure to 
ultraviolet light (88). This property classifies Res as a phytoalexin, compounds produced 
by plants in response to damage. In recent years, research on Res has described several 
beneficial effects of this compound to human health (Figure 5). Resveratrol has been 
reported to have both anticarcinogenic and cardioprotective activities, which could be 
attributed to its antioxidant and anticoagulant properties (89-94). Resveratrol has been 
reported to be effective in inhibiting platelet aggregation and lipid peroxidation, altering 
eicosanoid synthesis, modulating lipoprotein metabolism (95-97), and exhibiting 
vasorelaxing and anti-inflammatory activities (98). For its anticarcinogenic activities, 
potential mechanisms of Res action have been studied extensively, though there is no 
clear consensus on the matter. Resveratrol has been reported to inhibit the three major 
stages of carcinogenesis: initiation, promotion, and progression (99, 100). Anti-initiation 
activity was indicated by antioxidant and antimutagenic effects and induction of phase II 
drug-metabolism enzymes (101). Antipromotion activity was indicated by anti-
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inflammatory effects, and inhibition in vitro of cyclooxygenase and hydroperoxidase 
(101). Antiprogression activity was described as an induction of human promyelocytic 
leukemia cell differentiation (101). Resveratrol also inhibits the development of 
preneoplastic lesion in carcinogen-treated mouse mammary glands in culture and inhibits 
tumorogenesis in a mouse skin cancer model (101). Many in vitro studies have addressed 
the Res activities in breast cancer cells. Resvertrol exhibits an action in both hormone-
sensitive and hormone-resistant breast cancer cells. Resveratrol has also been reported to 
exhibit anti-initiation, antipromotion, and antiprogression activities in breast cancer cells, 
where these properties seem to be related to regulation of xenobiotic carcinogen 
metabolism and anti-inflammatory, antiproliferative, and proapoptotic effects. 
Chemoprevention of carcinogenesis by nontoxic chemical substances is regarded as a 
promising alternative strategy to therapy for control of human cancer. In recent years, 
many naturally occurring substances have been shown to protect against experimental 
carcinogenesis (13, 102-107). Although Res has shown remarkable promise as a potent 
chemopreventive agent in breast cancer in vitro, there is a long way to go for it to be 
developed as an agent for chemoprevention / treatment of cancer in clinical settings. 
Continued efforts are needed, especially well-designed preclinical studies in animal 
models.  
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Figure 5: Biochemical mechanisms responsible for chemopreventive and chemotherapeutic 
potential of resveratrol 
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1.8.2.  Limitations of Resveratrol use in Clinical Settings 
A variety of natural compounds are found in nature with unique medicinal values. 
Resveratrol is one of such hugely studied naturally occurring plant derived phyto-
estrogen, well studied for its medicinal properties. It is found in various vegetables, nuts, 
fruits including grapes and red wine. Res have been well explored for its plethora of 
medicinal properties in treatment of cancer and a wide range of other diseases (99, 108-
114). Resveratrol mediates its anti cancer activity by inducing apoptosis in cancer cells 
via modulating various signal transduction pathways and targeting different transcription 
factors responsible for uncontrolled growth of cancer cells (74, 115-119). Not only 
limited to in vitro studies, Res has also been successfully shown to reduce growth of 
primary tumor xenografts in animal model (120). In spite of its remarkable medicinal 
properties, Res cannot be used effectively as anticancer agent in clinical settings due to 
its poor efficacy in human body (121-125). The polyphenol Res is highly absorbed, 
metabolized and excreted yielding a rather low bioavailability (121-125). Approximately 
twenty different metabolites of Res have been found in plasma, urine of animals and 
humans (126-128). The main metabolites of Res found are in the forms of mono- and di-
glucuronides (trans- and/or cis-), mono- and disulfates and sulfoglucuronides (129-131).  
It has been observed that the plasma concentration of Res-metabolites is much higher 
than that of parent compound. The highest plasma Cmax of Res-metabolite (967 ng/mL, 
around 4.2 µM) was reported by Brown et al.  upon ingestion of 5 g micronized Res in 
comparison to that obtained (539 ng/mL, around 2.3 µM) after standard Res intake (132).  
Therefore, in order to improve the anticancer and antioxidant efficacy of Res and 
use it successfully against breast cancer and probably other diseases, there is a genuine 
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need to develop more effective and sensitive analogs of Res. To meet this goal, our 
collaborative team has synthesized active Res analogs (Figure 6 & Figure 7) (133). In 
these analogs we have maintained 3,4-dihydroxy substitution on the A ring while varying 
the substituents at C-4 position on the B ring along with inclusion of aza functionality in 
the conjugated system (133). The analogs synthesized were named as 3a-f (133). We 
have studied two of these analogs named TIMBD, 4-(E)-{(p-tolylimino)-methylbenzene-
1,2-diol; and HPIMBD, 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1, 2-diol (133), 
for their antiproliferative and cytotoxic properties on breast cancer cells. HPIMBD and 
TIMBD have been shown to inhibit breast cancer cell proliferation effectively and 
successfully with no cytotoxicity towards normal breast epithelial cells.  
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Figure 6: Chemical structure of aza-resveratrol analogs 
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Figure 7: Structural similarities and dissimilarities between 
resveratrol and Res-analogs 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
 
2.1. Cell Culture 
All studies were approved by Institutional Biosafety Committee and Institutional 
Review Board of UMKC. Human breast cancer cell lines (MDA-MB-231, MDA-MB-
468, MCF-7, BT-20 & T47D) and non-tumorigenic breast epithelial cell lines (MCF-
10A, HMEC & MCF-10F) were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). Experiments were performed in passages two to six of cells sub-
cultured from a frozen vial. Cells were grown in Dulbecco’s modified Eagle’s 
medium/F12 (50:50) media (Mediatech, Herndon,VA) at 37°C in 5% CO2 environment. 
Cells were grown to confluence into six-well plates for all experiments. Twenty four 
hours prior to treatment, cells were washed twice with phosphate-buffered saline (PBS). 
Breast epithelial cells ( MCF-10A, MCF-10F and HMEC) were then grown in phenol 
red-free Dulbecco’s modified Eagle’s medium/F12 (50:50), supplemented with 5% 
charcoal-dextran-stripped horse serum (Cocalico Biologicals, Reamstown, PA). Breast 
cancer cells (MDA-MB-231, MDA-MB-468, MCF-7, BT-20 & T47D) were grown in 
phenol red-free Dulbecco’s modified Eagle’s medium/F12 (50:50), supplemented with 
5% charcoal-dextran-stripped fetal bovine serum (Atlanta Biologicals, Lawrenceville, 
GA).  
2.2. Chemicals and Reagents 
17 β-Estradiol (E2), Resveratrol (Res) and Vitamin C (VC) were purchased from 
Sigma–Aldrich (St. Louis, MO). Resveratrol analogs TIMBD and HPIMBD were 
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provided by our collaborator team (133). 17β-Estradiol, Res and Res-analogs were 
dissolved in dimethylsulfoxide (DMSO) and vitamin C was dissolved in distilled water 
prior to treatments. The concentration of DMSO in control experiments or in 
experimental samples was always 1/1000th (v/v) of the final medium volume. 
Lipofectamine 2000TM was purchased from Invitrogen Inc. (Carlsbad, CA). Specific 
siRNAs for Nrf3, Notch 2, β catenin, E-Cadherin and control siRNA were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA).  
2.3. Treatment of breast cancer cells and non-tumorigenic breast epithelial cells 
with Resveratrol, Vitamin C, TIMBD and HPIMBD 
Human breast cancer cell lines (MDA-MB-231, MDA-MB-468, MCF-7, BT-20 
& T47D) and non-tumorigenic breast epithelial cell line (MCF-10A, HMEC & MCF-
10F) were treated with Res, TIMBD or HPIMBD (10-50 μM) for upto 72 hour. MCF-
10A cells were also treated with 1 mM vitamin C for up to 72 hours either in the presence 
or absence of E2. Resveratrol, TIMBD and HPIMBD were dissolved in 
dimethylsulfoxide (DMSO) prior to treatments. Cells that were treated with vehicle 
control DMSO (0.1%), were used as appropriate controls. Treated cells were washed with 
PBS and used for MTT assay, LDH assay, RT-PCR, western blot analyses and other 
assays according to established methods.  
2.4. si RNA Transfection 
Small interfering RNAs (siRNAs) for Nrf3, Notch 2, β catenin and control siRNA 
(scrambled) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). MCF-10A 
cells were transfected with siNrf3 (20 nmol/l) using Lipofectamine 2000TM transfection 
reagent (Invitrogen, Carlsbad, CA). Scrambled siRNA- (20 nmol/l) transfected MCF-10A 
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cells were used as a negative control. MDA-MB-231 cells were transfected with siNotch2 
(20 nmol/l) and siβ catenin (15 nmol/l) using same transfection reagent. Same 
concentrations of scrambled siRNAs were used as negative controls for siRNAs for 
Notch 2 and β-catenin. 
2.5. Real time RT-PCR 
Real time PCR was used to quantify mRNA expression levels of Nrf1, Nrf2, Nrf3, 
SOD3, NQO1, β-catenin, Wnt-5a, Wnt-7b and Frizzled-4. Our recently published study 
suggests that SOD3 and not SOD1 or SOD2 play important role in antioxidant-mediated 
prevention of E2-induced breast cancer in female ACI rats (49). After different 
treatments, total RNA from cultured cells was isolated using TRI Reagent (Molecular 
Research center, Inc.), according to the supplier’s protocols. Five μg total RNA was 
reverse transcribed using the superscript II reverse transcription system and an oligo-dT18 
primer (Invitrogen, Carlsbad, CA). After reverse transcription, RNase H (2 units/μl) was 
added to all samples to ensure degradation of the remaining RNA. Real-time PCR was 
performed in duplicate 25 μl reactions using human-specific Nrf1, Nrf2, Nrf3, SOD3 and 
NQO1 primers (Qiagen, Valencia, CA and Integrated DNA Technologies, Coralville, IA, 
USA) using the  iCycler iQ5 system (Bio-Rad Laboratories,Hercules, CA). The mRNA 
expression of cyclophilin, a housekeeping gene, was used for quantification and 
standardization purposes (134). The expression of the genes under study relative to 
cyclophilin were determined by dividing the number of c DNA molecules for the gene of 
interest by the number of cyclophilin c DNA molecules as reported previously (135). 
Data were analyzed from at least three different samples in each group.  
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Table 1: List of PCR-Primers and their sequences  
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2.6. Western blotting 
Western blot analyses were performed to quantify Nrf1, Nrf2, Nrf3, SOD3, 
NQO1, MMP2, MMP3, MMP9, E-Cadherin, Snail, Slug, Zeb 1, Zeb 2, Notch-2, β-
catenin, Beclin-1 , LC3I/II, Lamin and α-tubulin protein levels. Cell lysates were 
prepared in RIPA buffer with protease inhibitor cocktail (Sigma–Aldrich, St Louis, MO). 
Thirty micrograms of total protein isolated from quadruplicates of control or treated cells 
were size fractionated on a 12% SDS-polyacrylamide gel, and transferred onto PVDF 
membranes under standard conditions (36, 49). Membranes were blocked in 5% dry non-
fat milk/PBS/0.5% Tween-20 at room temperature for 2 hours. Affinity purified 
polyclonal antibodies against Nrf1, Nrf2, Nrf3, SOD3, NQO1, MMP2, MMP3, MMP9, 
E-Cadherin, Snail, Slug, Zeb 1, Zeb 2 (Santa Cruz Biotechnology, Santa Cruz, CA), 
Lamin, Notch-2, β-catenin, Beclin-1 and LC3I/II (Cell signaling Technology) were 
diluted 1:1500 in PBS/0.05% Tween-20 and used for immunodetection. After incubation 
overnight at room temperature with the primary antibody, membranes were washed four 
times for 8 min per wash using PBS/0.05%Tween-20. Horse radish peroxidase 
conjugated IgG was diluted 1:2000 in PBS/0.5% Tween-20 and used as a secondary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). After incubation for 2 hours at 
room temperature, the membrane was washed again as described above. 
Chemiluminescent detection was performed using the BM Chemiluminescence Detection 
kit (Roche, Indianapolis, IN) and Alpha Innotech FluorChem HD2 (Alpha Innotech, San 
Leandro, CA) gel documentation system.  Membranes probed for the above mentioned 
specific primary antibodies, were then washed in PBS/0.5% Tween-20 and re-incubated 
overnight at room temperature with α-tubulin monoclonal mouse antibody (Santa Cruz 
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Biotechnology, Santa Cruz, CA) diluted 1:2000 in PBS/0.05%Tween-20. Horse radish 
peroxidase-conjugated anti-mouse IgG antibody (Santa Cruz Biotechnology) was diluted 
1:2500 in PBS/0.05% Tween-20 and used as a secondary antibody for α-Tubulin 
detection. Secondary antibody was incubated with the membrane for 2 hours at room 
temperature prior to chemiluminescent detection using the method described above. 
2.7. Colony Formation assay 
For clonogenic cell survival assay about 500, each of MDA-MB-231 or T47D 
cells were treated with 5 μM, 10 μM and 25 μM of Res, HPIMBD and TIMBD for 48 
hour. About 500 viable MDA-MB-231 cells were transiently transfected with siRNAs for 
 catenin (30 nmol/l) and scrambled siRNA (30 nmol/l) for 48 hour (or untransfected 
MDA-MB-231 cells) were seeded in six-well plates and allowed to grow for 48 hours in 
phenol red-free complete media. The cells were then washed in PBS and incubated for 
additional 8 days in complete medium. The colonies obtained were washed with PBS and 
fixed in 10% formalin for 10 min and again washed twice with PBS followed by staining 
with crystal violet (0.1%w/v solution in 10% ethanol). The colonies were counted, 
photographed and compared with respective untreated cells. Each treatment was done in 
triplicate. 
2.8. Mammosphere Formation assay 
Mammosphere formation assay was carried out in ultra-low attachment plates 
(Corning, Lowell, MA). Briefly, 5000 viable T47D cells were seeded in ultra-low 
attachment plates. After 24 hours, cells were treated with 50 μM of Res, HPIMBD and 
TIMBD and were grown in serum-free DMEM/ F12 (50:50) medium supplemented with 
1x B27 supplement (Invitrogen), 20 ng/ml epidermal growth factor (Invitrogen), 20 
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ng/ml basic fibroblast growth factor (Invitrogen), 1 μg/ml hydrocortisone (BD 
Biosciences, Bedford, MA), 5 μg/ ml insulin (Invitrogen), 0.1% penicillin/streptomycin 
(Lonza, Walkersville, MD) and 4 μg/ml heparin calcium salt (Thermo Scientific) at 37°C 
under 5% CO2. After 6–8 days of incubation, mammospheres were viewed under the 
microscope and photographed. Three replicate wells from a 24-well plate were used for 
each experimental condition. 
2.9. Wound Healing assay 
Cell migration assay was used to study the metastatic potential of the cells. 
Briefly, confluent monolayers of MDA-MB-231 cells were treated with Res, HPIMBD 
and TIMBD at 50 μM doses for 24 hour. A scratch was made through the monolayer, 
using a standard 200 μl plastic pipette tip, washed twice with PBS and replaced in phenol 
red-free complete media. Cells migrate into the scratch area as single cells from the 
confluent sides. After 24 hour, the width of the scratch gap was viewed/measured under 
the microscope and photographed. Three replicate wells from a six-well plate were used 
for each experimental condition. 
2.10. Measurement of reactive oxygen species (ROS) production 
The production of ROS was measured by flow cytometry using 
dichlorofluoroscein diacetate (DCFDA; Invitrogen). Briefly, MCF-10A cells were treated 
with E2 (50 nM), Res (50 µM), TIMBD (50 µM) or HPIMBD (50 µM) using serum-free 
medium at different times in a 6-well plate. After treatment, the cells were washed with 
PBS and incubated with 10 μM DCFDA in PBS for 30 min at 37°C.  1 mM H2O2 treated 
cells, for 30 min were used as a positive control. After treatment, the cells were harvested 
and dissolved in 1 ml PBS with 1% FBS to measure the DCF emission at 525 ± 20 nm by 
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flow cytometer (BD Biosciences, San Jose, CA), and Mean Fluorescence Intensity (MFI) 
was measured and analyzed. 
2.11. 8-OH-dG formation assay 
8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative stress-mediated DNA 
damage marker was measured in MCF-10A cells treated with Res, TIMBD or HPIMBD 
in presence or absence of E2 for 48 hour. DNA was isolated from the cells after all the 
treatment. DNA was isolated using DNeasy blood and tissue kit (Qiagen, Valencia, CA) 
according to the supplier’s protocols with some modifications. To avoid possible spurious 
DNA oxidation diethylenetriamine pentaacetic acid (0.1 mM) and ascorbic acid (2 mM) 
were used throughout the DNA isolation process. DNase-free RNase (Sigma-Aldrich, St. 
Louis, MO) was used to degrade RNA as per supplier’s recommendations. The RNA-free 
DNA was used to estimate 8-OHdG levels using Oxiselect oxidative DNA damage 
ELISA-kit (Cell Biolabs, San Diego, CA) according to supplier’s protocols with some 
modifications. Briefly, 20 μg DNA was digested with 10 U DNase 1 (Qiagen, Valencia, 
CA) at 37°C for 30 min in presence of 100 mM MgCl2 and 1 M Tris-HCl (pH 7.4). After 
that, pH of digested DNA was adjusted to 5.2 with 3 M sodium acetate (pH 5.2). DNA 
reaction mixture was subjected to 1 μl of nuclease P1 (1 U/μl) digestion for 1.5 hour at 
37°C. After incubation, 1 M Tris-HCl (pH 8.0) was used to bring the pH back to 7.4, 
followed by treatment with 1 μl of alkaline phosphatase (1 U/μl stock) for 1 hour. The 
reaction mixture was then subjected to 1 μl of each phosphodiesterase I (0.01 U/μl) and 
phosphodiesterase II (0.01 U/μl) digestion for 30 min at 37°C. The reaction mixture was 
centrifuged for 5 min at 6000g and the supernatant was used for 8-OHdG ELISA assay. 
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2.12. Cell survival assay (MTT assay) 
The effects of Res, TIMBD and HPIMBD on cell viability were measured using 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The breast 
cancer cell lines tested were MCF-7, T47D, MDA-MB-231, MDA-MB-468 and BT-20. 
The non-neoplastic breast cell lines tested were MCF-10A, MCF-10F and HMEC. 
Briefly, 2000 cells were seeded in 96-well plates and treated with increasing dosages 
(6.25 µM, 12.5 µM, 25 µM, 50 µM and 100 µM) of Res, TIMBD or HPIMBD for 72 
hour. 0.5 mM hydrogen peroxide (H2O2) was used as positive control and 10% dimethyl 
sulfoxide (DMSO) as negative control. After 96 hour treatment was terminated, the 
medium was replaced with 100 µl of 1mg/ml MTT reagent and incubated at 37°C for 3.5 
hour. The medium was removed carefully and purple colour formazan crystals were 
dissolved in 200 μl DMSO containing 25 μl of Sorenson’s glycein buffer by gentle 
shaking on a shaker. The color formation was measured using Benchmark Microplate 
Reader (Bio-Rad Laboratories, Hercules, CA) with absorbance at 570 nm and reference 
at 650 nm. 
2.13. Cell survival assay (LDH assay) 
The tests of LDH release were conducted using Pierce LDH Cytotoxicity Assay 
Kit (# 88953). The breast cancer cell lines tested were MCF-7, T47D, MDA-MB-231, 
MDA-MB-468 and BT-20. The non-neoplastic breast cell lines tested were MCF-10A, 
MCF-10F and HMEC. All the cells were plated in a 96-well plate (10,000 cells/well) in 
Dulbecco’s modified Eagle’s medium/F12 (50:50) media (Mediatech, Herndon,VA) 
supplemented with fetal bovine serum and incubated overnight at 37°C in 5% CO2 
environment. Next day cells were treated with increasing concentrations (6.25 µM, 12.5 
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µM, 25 µM, 50 µM and 100 µM) of Res, TIMBD or HPIMBD for 72 hour. Following 
treatment with compounds, 50 µl supernatant from each well was transferred into a new 
96-well plate, 50 µl of reaction mixture from the assay kit was added to each well of the 
microplate. After incubation at room temperature for 30 minutes, 50 µl of stop solution 
was added to each well to stop the reaction. Activity of LDH was determined by 
spectrophotometric absorbance at 490 nm and 680 nm. Cell viability was measured in 
replicate wells and each set of experiment was carried out at a minimum of three times.  
2.14. Caspase-3/7 activity assay 
The caspase-3/7 activities were measured using the Apo-ONE Homogeneous 
Caspase-3/7 Assay kit (Promega, Madison, WI) according to the manufacturer’s protocol. 
Briefly, MDA-MB-231 and T47D cells were seeded in a 96-well flat bottom plates 
(Corning, Lowell, MA). Cells were treated with 50 µl of Res, TIMBD or HPIMBD for 24 
hour. After treatment cells were lysed with lysis buffer which contained substrate for 
caspase (Z-DEVD-R110). Cells were incubated with lysis buffer for 6 hour at room 
temperature. Finally, Caspase activity was determined by measuring the fluorescence at 
485/535 nm wavelengths.   
2.15. Autophagosome staining with the FITC-fluorescent MAP-LC3 antibody 
Treated or untreated MDA-MB-231 cells (with 25 µM of Res, TIMBD or 
HPIMBD for 12 hour) were fixed with 4% paraformaldehyde in PBS for 15 min, 
permeabilized with 0.3% Triton X-100 and blocked with 2% BSA for 30 min. Then cells 
were incubated with primary antibodies against LC3 overnight at 4°C, washed with PBS, 
and incubated for another 60 min with an Alexa Fluor®-conjugated antibody 
(Invitrogen). The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma). 
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A Zeiss LSM 710 confocal microscope system (Carl Zeiss, Germany) was used for 
colocalization analysis. 
2.16. Co-Immunoprecipitation (Co-Ip) Assay 
A Pierce kit (Pierce Biotechnology, Inc., Rockford, IL; Catalog #26149) was used 
for co-immunoprecipitation of interacting proteins, Nrf2 and Nrf3. After direct covalent 
immobilization of the primary antibody (Nrf2 antibody, Santa Cruz, CA) to amino link 
plus resin, immunoprecipitation of the Nrf2 protein (bait protein), and co-
immunoprecipitation of interacting  Nrf3 protein (prey protein) were performed using  
spin columns. The experiments were repeated reversing bait and prey proteins. Now Nrf3 
antibody (Santa Cruz, CA) was covalently immobilized to the resin and 
immunoprecipitated, the blot was probed to detect co-immunoprecipitation of Nrf2 as 
prey protein. Unspecific interactions were identified by using the provided control gel 
and substituting IgG for the specific antibody. Eluted fractions were then subjected to 
western blotting for identification of the interacting proteins. 
2.17. Statistical analysis 
Statistical analyses were performed by using Sigma Plot 11.0 (Systat Software, 
San Jose, CA) and IBM SPSS Statistics 19 software (IBM Inc, Armonk, NY). All cell 
culture treatments were done in quadruplicate. The Student’s t-test analysis was used to 
calculate p values for the comparison between two groups. One-way analysis of variance 
(ANOVA) and least significant difference (LSD) post hoc analyses were used to calculate 
p values for comparisons among all groups. A p value of ≤ 0.05 was considered 
significant as shown by ‘*’ or ‘#’. 
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CHAPTER 3 
 
IDENTIFICATION AND CHARACTERIZATION OF RESVERATROL ANALOGS 
IN INHIBITING BREAST CANCER CELL GROWTH AND POSSIBLE 
MECHANISM OF ACTION OF CHEMOPREVENTION 
 
3.1. Introduction 
Breast cancer is one of the leading causes of deaths among women in the United 
States (1-3). Most breast cancers are estrogen-dependent and the contribution of 
estrogens in development of breast cancer is well accepted (4-19). As a result, estrogens 
have been added to the list of known human carcinogens (20-22). Apart from estrogen-
receptor dependent pathways, estrogen-metabolism mediated oxidative stress-associated 
pathways are implicated in the development of breast cancer (12, 13, 15). These estrogen-
receptor independent, oxidative stress-associated pathways can be successfully targeted 
for chemoprevention of breast cancer. Our aim is to develop potentially effective 
pharmacological agents against breast cancer development by targeting estrogen-induced 
oxidative stress pathways.  
The fact that oxidative stress plays an important role in breast cancer development 
(4, 5) has encouraged people to have antioxidant-rich foods in their daily diets. In 
estrogen-induced carcinogenesis, metabolic activation of estrogen produces oxidative 
stress during redox cycling between estrogenic catechols and quinones (15, 18). This 
oxidative stress can damage DNA, proteins and lipids (7, 19). These damages can modify 
expression levels of cellular phase-II detoxifying enzymes (36, 37). Expression of cell 
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cycle regulatory genes can also change as a result of oxidative stress leading to abnormal 
cell proliferation (37). All these cellular events collectively can ultimately lead to breast 
tumor development.  
The use of prototypic naturally occurring antioxidant vitamin C in cancer 
chemoprevention and treatment has been reported extensively in the literature (13, 120, 
136-138). The mechanism of breast cancer chemoprevention by antioxidants is not well 
understood and is the focus of our present studies. We have characterized in our studies 
the antioxidant mechanism of the naturally occurring antioxidants, Res, VC; and Res-
analogs, TIMBD and HPIMBD.   
Resveratrol is an extensively studied phytoestrogen found in grapes, nuts, red 
wine and various plants, well known for its protective role against various diseases 
including cancer (89-94). Amongst its multiple activities, anticancer activity, by targeting 
cancer cells and induction of apoptosis in cancer cells is an important one (74, 115-119). 
Resveratrol has been shown to modulate several signaling kinases, transcription factors 
and other targets leading to cancer cell death (115-119). But Res is not effective as 
anticancer agent in vivo. Its clinical application is limited because of its poor efficacy in 
human body (121-125). Thus, to improve anticancer and antioxidant efficacy Res and to 
use it as a successful agent targeting breast cancer, pharmacologically active resveratrol 
analogs have been synthesized. These Res-analogs have been synthesized in such a way 
that they are predicted to have better stability than that of the parent compound, Res and 
have been tested for their ability to inhibit growth of breast cancer cells. 
Our newly synthesized aza Res-analog compounds HPIMBD, 4-(E)-{(4-
hydroxyphenylimino)-methylbenzene, 1,2-diol} and TIMBD, 4-(E)-{(p-tolylimino)-
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methylbenzene-1,2-diol}(133), have effectively inhibited the growth of breast cancer 
cells and have no/minimal toxicity towards normal cells (133). To further delineate the 
mechanisms responsible for higher anti cancer potency of HPIMBD and TIMBD, we 
have aimed at finding out its antioxidant potentials.  
 In this current work we have also shown the contribution of HPIMBD and 
TIMBD in providing antioxidant defense in human breast epithelial cells. In our previous 
studies we have shown that estrogen-induced breast carcinogenesis is initiated by down-
regulation of expression of the antioxidant enzymes, superoxide dismutase 3 (SOD3, also 
known as extracellular superoxide dismutase) (49) and NAD(P)H-quinone 
oxidoreductase 1 (NQO1) (36). In this present study, we have shown that our novel and 
potent resveratrol analogs HPIMBD and TIMBD, synthesized by our collaborating team 
(133), function to inhibit E2-dependent breast cancer development by up-regulation of 
the expression of SOD3 and NQO1.  We have also provided evidence how these analogs 
mediate antioxidant defense through down-regulation of cellular reactive oxygen species 
(ROS) generation and 8-OHdG formation.  
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3.2. Results 
3.2.1. Res-analogs TIMBD and HPIMBD inhibit proliferation in breast cancer cells 
better than resveratrol and have no effect on non-tumorigenic breast epithelial cells. 
 The newly synthesized Res-analogs were tested and compared with Res for their 
antiproliferative effects using MTT assay, using five different breast cancer cell lines and 
three non-tumorigenic breast epithelial cell lines (Figures 8-15). The breast cancer cell 
lines tested were MCF-7, T47D, MDA-MB-231, MDA-MB-468 and BT-20 (Figures 8-
12). The non-neoplastic breast cell lines tested are MCF-10A, MCF-10F and HMEC 
(Figures 13-15). MDA-MB-231, MDA-MB-468 and BT-20 are triple negative breast 
cancer cell lines; MCF-7 and T47D are estrogen receptor positive human breast cancer 
cell lines. All compounds exhibited antiproliferative effects against all five breast cancer 
cell lines (Figures 8-12) at 50 µM concentration. Compounds HPIMBD and TIMBD 
exhibited most potent antiproliferative activity against all breast cancer cell lines 
compared to Res. The compounds HPIMBD and TIMBD exhibited lower IC50 values 
compared to Res against all five breast cancer cell lines tested. HPIMBD showed IC50 
values of 4.8, 29, 44, 41, 32 µM and TIMBD showed IC50 values of 3.62, 21, 32, 38, 31 
µM against MDA-MB-468, MDA-MB-231, T47D, MCF-7 and BT-20 breast cancer cell 
lines, respectively as compared to Res with IC50 values of 41, 66, 76, 77 and 99 µM, 
respectively (Table 2). None of the newly synthesized resveratrol analogs exhibited any 
cytotoxic effects against MCF-10A, MCF-10F and HMEC cells at 50 µM concentrations 
(Figures 13-15) suggesting they are non-cytotoxic towards normal breast cells and 
selectivity to cancer cells. 
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Figure 8: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD 
and TIMBD against human triple negative breast cancer cells, MDA-MB-
231. The cells were treated with increasing concentrations of resveratrol 
(Res), HPIMBD or TIMBD for up to 72 hours and were assessed for 
cytotoxicity by MTT assay. 1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
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Figure 9: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD 
and TIMBD against human triple negative breast cancer cells, MDA-MB-
468. The cells were treated with increasing concentrations of resveratrol 
(Res), HPIMBD or TIMBD for upto 72 hour and were assessed for 
cytotoxicity by MTT assay. 1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
40 
 
 
  
Figure 10: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human breast cancer cells, MCF-7. The cells were treated with 
increasing concentrations of resveratrol (Res), HPIMBD or TIMBD for upto 72 
hour and were assessed for cytotoxicity by MTT assay. 1mM H2O2 was used 
as positive control. 
* P≤ 0.05 compared to control 
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Figure 11: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human breast cancer cells, T47D. The cells were treated with 
increasing concentrations of resveratrol (Res), HPIMBD or TIMBD for upto 72 
hour and were assessed for cytotoxicity by MTT assay. 1mM H2O2 was used as 
positive control. 
* P≤ 0.05 compared to control 
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Figure 12: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human triple negative breast cancer cells, BT-20. The cells 
were treated with increasing concentrations of resveratrol (Res), HPIMBD or 
TIMBD for upto 72 hour and were assessed for cytotoxicity by MTT assay. 
1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
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Figure 13: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against MCF-10A, non-neoplastic human breast epithelial cells. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
MTT assay. 1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
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Figure 14: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against MCF-10F, non-neoplastic human breast epithelial cells. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
MTT assay. 1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
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Figure 15: Antiproliferative activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against HMEC, non-neoplastic human breast epithelial cells. The cells 
were treated with increasing concentrations of resveratrol (Res), HPIMBD or 
TIMBD for upto 72 hour and were assessed for cytotoxicity by MTT assay. 
1mM H2O2 was used as positive control. 
* P≤ 0.05 compared to control 
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Table 2. The IC50 for different breast cell lines treated with Res, HPIMBD or 
TIMBD.   HPIMBD and TIMBD have better IC50 than resveratrol (Res) against 
breast cancer cell lines; HPIMBD and TIMBD have no effect on non-tumorigenic 
human breast epithelial cells 
 
IC50 (11M) IC50 (11M) IC50 (11M) 
Cell line Res HPIMBD TIMBD 
MDA-MB-468 41 4.8 3.62 
MDA-MB-231 66 29 21 
T47D 76 44 32 
M CF-7 77 41 38 
BT-20 99 32 31 
M CF-I0A, M CF- No efiect No efiect No efiect 
10F, HMEC 
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3.2.2 Res-analogs TIMBD and HPIMBD induce cytotoxicity in breast cancer cells 
better than resveratrol and have no effect on non-tumorigenic breast epithelial cells. 
Breast cancer cell lines MCF-7, T47D, MDA-MB-231, MDA-MB-468 and BT-20 
were treated with different doses of TIMBD and HPIMBD (0, 6.25, 12.5, 25 and 50µM) 
and 50 µM Res for upto 72 hour (Figures 16-22). The extent of cell death was measured 
72 hour of treatment by LDH release assays. The amount of LDH released from dying 
cells is directly proportional to cell death. HPIMBD at 50 µM dose significantly caused 
about 32 % and TIMBD at 50 µM dose significantly caused about 35 % increase in LDH 
release in MCF-7 and T47D cells (Figures 18 & 19). HPIMBD at 50 µM dose 
significantly caused about 38 % and TIMBD at 50 µM dose significantly caused about 40 
% increase in LDH release in triple negative breast cancer cells; MDA-MB-231, MDA-
MB-468 and BT-20. (Figures 16, 17 & 20). 50 µM of Res treatment for 72 hour caused 
about 22 % increase in LDH release in MCF-7 and T47D cells (Figures 18 & 19) and 
about 25 % increase in MDA-MB-231, MDA-MB-468 and BT-20 cells (Figures 16, 17 & 
20). To examine the cytotoxic effect of TIMBD and HPIMBD on non-tumorigenic 
human breast epithelial cells, MCF-10A and MCF-10F cells were treated with above 
mentioned doses of TIMBD and HPIMBD. LDH release was measured in these cells 
after 72 hour. TIMBD and HPIMBD did not show any cytotoxic effect on non-
tumorigenic breast epithelial cells treated with upto a dose of 50 µM (Figures 21 & 22). 
From these results in can be suggested that Res-analogs TIMBD and HPIMBD can 
significantly induce cytotoxic effect in a dose-dependent manner and upto a dose of 50 
µM, they do not induce any cytotoxic effect towards non-tumorigenic breast epithelial 
cells.   
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Figure 16: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human triple negative breast cancer cells, MDA-MB-231. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
LDH assay.  
* P≤ 0.05 compared to control 
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Figure 17: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human triple negative breast cancer cells, MDA-MB-468. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
LDH assay.  
* P≤ 0.05 compared to control 
50 
 
 
  
Figure 18: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and TIMBD 
against human estrogen-receptor positive breast cancer cells, MCF-7. The cells 
were treated with increasing concentrations of resveratrol (Res), HPIMBD or 
TIMBD for upto 72 hour and were assessed for cytotoxicity by LDH assay. 
 * P≤ 0.05 compared to control 
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Figure 19: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and TIMBD 
against human estrogen-receptor positive breast cancer cells, T47D. The cells 
were treated with increasing concentrations of resveratrol (Res), HPIMBD or 
TIMBD for upto 72 hour and were assessed for cytotoxicity by LDH assay. 
 * P≤ 0.05 compared to control 
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Figure 20: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against human triple negative breast cancer cells, BT-20. The cells 
were treated with increasing concentrations of resveratrol (Res), HPIMBD or 
TIMBD for upto 72 hour and were assessed for cytotoxicity by LDH assay.  
* P≤ 0.05 compared to control 
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Figure 21: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against MCF-10A, non-neoplastic human breast epithelial cells. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
LDH assay.  
* P≤ 0.05 compared to control 
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Figure 22: Cytotoxic activity of Aza-resveratrol analogs, HPIMBD and 
TIMBD against MCF-10F, non-neoplastic human breast epithelial cells. The 
cells were treated with increasing concentrations of resveratrol (Res), 
HPIMBD or TIMBD for upto 72 hour and were assessed for cytotoxicity by 
LDH assay.  
* P≤ 0.05 compared to control 
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3.2.3. Res-analogs are more potent to mediate antioxidant defense by reducing ROS 
production. 
We examined whether treatment with HPIMBD or TIMBD would decrease 
cellular reactive oxygen species (ROS) levels in MCF-10A cells better than Res. As 
shown in Figure 23, ROS production was significantly lower when treated with 50 µM of 
HPIMBD (Figure 23 A) or TIMBD (Figure 23 B) for 6 hour, as compared to control as 
well as E2. Moreover, treatment with 50 µM of Res did not decrease ROS production in 
MCF-10A cells. 1 mM concentration of H2O2 treatment was used as a positive control 
(Figure 23 A & B). These observations demonstrate that Res-analogs are more potent to 
mediate antioxidant defense to the breast epithelial cells by reducing cellular ROS 
production, and are better than Res.  
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Figure 23: Res-analogs HPIMBD (A) and TIMBD (B) significantly scavenge reactive oxygen 
species (ROS) in MCF-10A cells treated for 6 hour. * P≤ 0.05 compared to control;   # P≤ 0.05 
compared to E2.   
 
 
(A) (B) 
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3.2.4. Res-analogs are more potent to mediate antioxidant defense by reducing 
oxidative DNA damage. 
DNA 8-OHdG, marker of oxidative DNA damage, was quantified in human non-
tumorigenic breast epithelial cells MCF-10A after treatment with Res, TIMBD or 
HPIMBD in the presence or absence of E2. About 3-fold increase (P <0.05) in 8-OHdG 
levels was observed in E2-treated MCF-10A cells compared to vehicle treated control 
(Figure 24 A & B). 8-OHdG levels were significantly decreased in HPIMBD (Figure 24 
A) and TIMBD (Figure 24 B)-treated groups as compared to vehicle-treated control in 
MCF-10A cells. No significant differences in 8-OHdG levels were detected in MCF-10A 
DNA samples treated with Res, Res + E2, TIMBD + E2 and HPIMBD + E2-treated 
groups compared to vehicle-treated control but 8-OHdG levels were significantly 
decreased in Res, Res + E2, TIMBD, TIMBD + E2, HPIMBD and HPIMBD + E2-treated  
groups as compared to E2 treated MCF-10A cells (Figure 24 A &  24 B). These results 
suggest the antioxidant properties of TIMBD and HPIMBD in prevention of oxidative 
DNA damage in breast epithelial cells.  
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Figure 24: Res-analogs HPIMBD (A) and TIMBD (B) significantly down-regulate 
oxidative DNA damage in MCF-10A cells treated for 48 hour. * P≤ 0.05 compared to 
control;   # P≤ 0.05 compared to E2.   
 
 
 
 
 
 
(B) (A) 
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3.2.5. Natural antioxidants Res and VC reverse estrogen-mediated decrease in 
NQO1 and SOD3 mRNA and protein expression levels 
mRNA and Protein expression levels of NAD(P)H:quinone oxidoreductase 1 
(NQO1) were quantified in MCF-10A cells treated with E2 (50 nM) for up to 48 hour. 
Significant decreases in NQO1 mRNA as well as protein expression levels were 
determined (Figure 25 A & 25 B). Resveratrol (50 μM) and  (1 mM) treatment reversed 
E2-mediated decrease in NQO1 mRNA as well as protein expression levels and 
significantly increased NQO1 mRNA and protein expression levels in MCF-10A cells 
treated for upto 48 hour (Figure 25 A & 25 B). The fold changes in NQO1 protein 
expression levels in MCF-10A cells treated with E2, Res, Res + E2,  VC and VC + E2 for 
48 hour were 0.48, 3.28, 3.15, 2.24 and 1.12, respectively, compared to vehicle-treated 
cells (Figure 25 B). mRNA and protein expression levels of SOD3 were quantified in 
MCF-10A cells treated with E2 (50 nM) for up to 48 hour. A significant decrease in 
SOD3 mRNA as well as protein expression levels was detected compared to control cells 
(Figure 25 C & D). Resveratrol (50 μM) and  VC (1 mM) treatment reversed E2-
mediated decrease in SOD3 mRNA as well as protein expression levels and further, 
significantly increased SOD3 mRNA and protein expression levels in MCF-10A cells 
treated for up to 48 hour (Figure 25 C & 25 D). The fold changes in SOD3 protein 
expression levels in MCF-10A cells treated with E2, Res, Res + E2,  VC and VC + E2 for 
48 hour were 0.42, 3.84, 3.79, 2.32 and 2.18, respectively, compared to vehicle-treated 
controls (Figure 25 D).  
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Figure 25: Antioxidants Res and VC reverse E2-mediated decrease in Phase-II 
detoxifying enzymes, NQO1 and SOD3, at both mRNA and protein levels. (A) NQO1 
mRNA expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res, Res + 
E2, 1 mM VC or VC + E2 for 24 hour; (B) NQO1 protein expression levels in MCF-10A 
cells treated with 50 nM E2, 50 µM Res, Res + E2, 1mM VC or VC + E2 for 48 hour; 
(C) SOD3 mRNA expression levels in MCF-10A cells treated with 50 nM E2, 50 µM 
Res, Res + E2, 1 mM VC or VC + E2 for 24 hour; and (D) SOD3 protein expression 
levels in MCF-10A cells treated with 50 nM E2, 50 µM Res, Res + E2, 1 mM VC or VC 
+ E2 for 48 hour. 
 ‘*’ indicates p value ≤ 0.05 compared with respective controls. 
 
 
(A)
) 
(C) 
(B) (D) 
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3.2.6. Res-analogs are  more potent to mediate antioxidant defense by inducing 
phase-II detoxifying enzymes SOD3 (specific one from superoxide dismutase family) 
and NQO1 
We wanted to delineate the mechanism of antioxidant defense by Res-analogs 
TIMBD and HPIMBD. We were interested in finding out if TIMBD and HPIMBD could 
moderate the cellular levels of phase-II detoxifying enzymes, SOD3 and NQO1. mRNA 
and protein expression levels of SOD3 were quantified in MCF-10A cells treated with E2 
(50 nM) for upto 72 hour. A significant decrease in SOD3 mRNA as well as protein 
expression levels was detected compared to control cells (Figure 26 & Figure 27). 50 μM 
of Res or TIMBD treatment reversed E2-mediated decrease in SOD3 mRNA (Figure 26 
A) as well as protein (Figure 26 B & C) expression levels and further, significantly 
increased SOD3 mRNA and protein expression levels in MCF-10A cells treated for upto 
72 hour. The fold changes in SOD3 protein expression levels in MCF-10A cells treated 
with Res or TIMBD for 48 hour were 3.53 and 4.89, respectively, compared to vehicle-
treated controls (Figure 26 C). It was also demonstrated that, 50 μM of Res or HPIMBD 
treatment reversed E2-mediated decrease in SOD3 mRNA (Figure 27 A) as well as 
protein (Figure 27 B & C) expression levels and further, significantly increased SOD3 
mRNA and protein expression levels in MCF-10A cells treated for upto 72 hour. The fold 
changes in SOD3 protein expression levels in MCF-10A cells treated with Res or 
HPIMBD for 48 hour were 3.50 and 3.44, respectively, compared to vehicle-treated 
controls (Figure 27 C).  
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An enzyme responsible for converting E2-quinones to catechol is NQO1. Our 
results demonstrated that treatment with 50 µM TIMBD (Figure 28) for upto 72 hour 
inhibited E2-mediated decrease in NQO1 mRNA (Figure 28 A) and protein (Figure 28 B 
& C) expression levels and significantly increased NQO1 mRNA protein expression 
levels in MCF-10A cells. The fold changes in NQO1 protein expression levels in MCF-
10A cells treated with Res or TIMBD for 72 hour were 1.25 and 4.23, respectively, 
compared to vehicle-treated controls (Figure 28 C). It was also demonstrated that 
treatment with 50 µM HPIMBD (Figure 29) for upto 72 hour inhibited E2-mediated 
decrease in NQO1 mRNA (Figure 29 A) and protein (Figure 29 B & C) expression levels 
and further increased NQO1 mRNA and protein expression levels in MCF-10A cells 
(Figure 29 A, B & C). The fold changes in NQO1 protein expression levels in MCF-10A 
cells treated with Res or HPIMBD for 72 hour were 1.25 and 4.12, respectively, 
compared to vehicle-treated controls (Figure 29 C).   
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Figure 26: Novel Res-analog TIMBD reverses E2-mediated decrease in Phase-II 
detoxifying enzyme SOD3, at both mRNA and protein levels. (A) SOD3 mRNA 
expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res or 50 µM 
TIMBD for 24 hour; (B) SOD3 protein expression levels in MCF-10A cells treated with 
50 nM E2, 50 µM Res or 50 µM TIMBD for upto 96 hour; and (C) Representative 
Western blot showing increased SOD3 protein expression levels in MCF-10A cells 
treated with 50 nM E2, 50 µM Res or 50 µM TIMBD for 48 hour.  
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
(A) 
(C) 
(B) 
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Figure 27: Novel Res-analog HPIMBD reverses E2-mediated decrease in Phase-II 
detoxifying enzyme SOD3, at both mRNA and protein levels. (A) SOD3 mRNA 
expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res or 50 µM 
HPIMBD for 24 hour; (B) SOD3 protein expression levels in MCF-10A cells treated with 
50 nM E2, 50 µM Res or 50 µM HPIMBD for upto 96 hour; and (C) Representative 
Western blot showing increased SOD3 protein expression levels in MCF-10A cells 
treated with 50 nM E2, 50 µM Res or 50 µM HPIMBD for 48 hour. 
 ‘*’ indicates p value ≤ 0.05 compared with respective controls. 
(C) 
(A) (B) 
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Figure 28: Novel Res-analog TIMBD reverses E2-mediated decrease in Phase-II 
detoxifying enzyme NQO1, at both mRNA and protein levels. (A) NQO1 mRNA 
expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res or 50 µM 
TIMBD for 24 hour; (B) NQO1 protein expression levels in MCF-10A cells treated with 
50 nM E2, 50 µM Res or 50 µM TIMBD for upto 96 hour; and (C) Representative 
Western blot showing increased NQO1 protein expression levels in MCF-10A cells 
treated with 50 nM E2, 50 µM Res or 50 µM TIMBD for 72 hour.  
 ‘*’ indicates p value ≤ 0.05 compared with respective control 
  
(A) (B) 
(C) 
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Figure 29: Novel Res-analog HPIMBD reverses E2-mediated decrease in Phase-II 
detoxifying enzyme NQO1, at both mRNA and protein levels. (A) NQO1 mRNA 
expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res or 50 µM 
HPIMBD for 24 hour; (B) NQO1 protein expression levels in MCF-10A cells treated 
with 50 nM E2, 50 µM Res or 50 µM HPIMBD for upto 96 hour; and (C) Representative 
Western blot showing increased NQO1 protein expression levels in MCF-10A cells 
treated with 50 nM E2, 50 µM Res or 50 µM HPIMBD for 72 hour.   
 ‘*’ indicates p value ≤ 0.05 compared with respective control 
(A) (B) 
(C) 
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3.3. Discussion 
Long-term exposure to the female sex hormone estrogen has been associated with 
the initiation and progression of breast cancer (5-7). However, the mechanisms of E2-
induced breast carcinogenesis are not clear. It has been suggested that estrogen 
metabolism plays a major role in the onset of estrogen-induced breast cancer (15). 
Oxidative stress produced by redox cycling between catechol estrogens and estrogen 
quinones has been suggested to play a critical role in estrogen-induced breast cancer (5, 
6). These reactive oxygen species generated during estrogen-redox cycling can react with 
DNA to form apurinating adducts that are more likely to result in DNA mutations and 
ultimately causing cancer (37).  
In spite of all these studies suggesting important role of oxidative stress in 
development of breast cancer, the underlying mechanism is still not clearly understood. 
Therefore, it is of utmost importance to dissect out the molecular mechanisms of 
oxidative stress mediated breast cancer, of particular E2-mediated breast cancer and, 
accordingly, develop therapeutic interventions that target these pathways. 
A plenty of non-synthetic natural compounds are found with unique medicinal 
values. One of the hugely studied naturally occurring plant derived phyto-estrogen is 
namely resveratrol (Res), well studied for its medicinal properties. It is found in various 
vegetables, nuts, fruits including grapes and red wine. Resveratrol has been well explored 
for its plethora of medicinal properties in treatment of cancer and a wide range of other 
diseases (89-94). Resveratrol mediates its anticancer activity by inducing apoptosis in 
cancer cells via modulating various signal transduction pathways and targeting different 
transcription factors responsible for uncontrolled growth of cancer cells (115-119). 
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Although Res has been successfully shown to reduce growth of primary tumor xenografts 
in rodent (120), its use has been limited in clinical applications due to its poor 
effectiveness in human body (121-125). Therefore, pharmacologically active Res-analogs 
have been synthesized by our collaborative team (133) in order to improve its antioxidant 
and anticancer efficacy. The analogs synthesized were named as HPIMBD and TIMBD 
(133), have extensively studied for their antiproliferative properties on breast cancer 
cells. TIMBD and HPIMBD have shown to inhibit breast cancer cell proliferation 
effectively and successfully with no or least toxicity towards normal breast epithelial 
cells.  
In this current work we have shown the potency of TIMBD and HPIMBD in 
preferentially inhibiting the proliferation of breast cancer cells. We found the IC50 of 
TIMBD and HPIMBD is <5 µM in the breast cancer cell line MDA-MB-468 derived 
from African American breast cancer patient. It is reported that IC50 value of <5 µM is 
well within the acceptable range for evaluation of a drug for efficacy and safety in a 
clinical setting (139, 140). Our novel compounds TIMBD and HPIMBD were tested for 
their antiproliferative and cytotoxic effects against human breast cancer cell lines MCF-7, 
T47D, MDA-MB-231, MDA-MB-468, BT-20 as well as human normal breast cell lines 
MCF-10A, MCF-10F and HMEC by MTT and LDH assays, respectively. These 
compounds were compared with Res for their cytotoxic effects on above-mentioned cell 
lines. Our novel compounds TIMBD and HPIMBD exhibited antiproliferative effects 
(Figures 8-12) and cytotoxic effects (Figures 16-20) against all breast cancer cell lines 
and they showed better cytotoxicity than Res. The compounds TIMBD and HPIMBD 
exhibited IC50 value of 21 and 29 µM against MDA-MB-231, and 32 and 44 µM against 
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T47D breast cancer cell lines, respectively, as compared to Res with IC50 value of 66 and 
76 µM, respectively (Table 2). None of the novel-analogs exhibited any antiproliferative 
(Figures 13-15) or cytotoxic (Figures 21 & Figure 22) effects against human non-
tumorigenic breast epithelial cells MCF-10A, MCF-10F and HMEC at 50 µM 
concentrations, which suggest the safety of our novel Res-analogs towards normal breast 
epithelial cells and specificity towards cancer cells. Thus, in this current study we aimed 
at developing TIMBD and HPIMBD as a novel therapeutic compound for treatment of 
breast cancer with minimal or no toxicity towards normal breast epithelial cells.  
Studies from our laboratory and that of others have already shown oxidative-DNA 
damage induced by estrogen (36, 37). In this present study we wanted to examine the 
protective effects of Res-analogs TIMBD, HPIMBD as well as prototypic antioxidant Res 
in inhibition of cellular ROS production and inhibition of oxidative DNA damage in 
MCF-10A cells. We measured the levels of ROS in MCF-10A cells treated with 50 nM 
E2, 50 µM Res, 50 µM TIMBD or 50 µM HPIMBD for 6 hour (Figure 23). We 
demonstrated that treatment with TIMBD or HPIMBD significantly decreased ROS 
production in MCF-10A cells as compared to E2 as well as vehicle-treated control 
(Figure 23). 50 µM Res did not decrease ROS production in MCF-10A cells treated for 6 
hour. These observations demonstrate that Res-analogs are more potent to mediate 
antioxidant defense to the breast epithelial cells by reducing cellular ROS production, and 
are better than Res. We measured the levels of  8-OHdG which is  a known marker of 
oxidative DNA damage in MCF-10A cells treated with Res, TIMBD or HPIMBD with or 
without E2 for 48 hour. We demonstrated that E2-treatment significantly increased 8-
OHdG levels in MCF-10A cells (Figure 24 A & 24 B). 8-OHdG levels were significantly 
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decreased in HPIMBD (Figure 24 A) and TIMBD (Figure 24 B)-treated cells as 
compared to vehicle-treated control, but not with Res-treatment (Figure 24 A & 24 B). 
These studies suggest a protective role of TIMBD and HPIMBD against oxidative DNA 
damage (Figure 24 A & 24 B).  
In order to elucidate the molecular mechanisms by which Res-analogs TIMBD 
and HPIMBD mediate antioxidant defense to the human breast-epithelial cells, we 
targeted to study their effects in regulation of phase-II detoxifying enzymes. A large 
number of epidemiological, clinical and experimental evidences provide newer 
approaches for cancer chemoprevention (141-144). Induction of antioxidant phase-II 
detoxifying enzyme(s) is one such approach for breast cancer chemoprevention that can 
be used to inhibit the overproduction of oxidative stress in the process of estrogen 
induced breast cancer (36, 49, 145, 146). The phase II detoxifying enzymes such as SOD 
and NQO1 are known to scavenge harmful reactive oxygen species. The role of 
Superoxide dismutase 3 (SOD3) in prevention of E2-induced breast cancer has been 
reported recently (49). SOD3 is a key enzyme involved in regulation of oxidative stress, 
and its increased expression can prevent estrogen-induced breast cancer. In this respect, 
we have shown in our previous studies that mRNA, protein and enzyme activity of SOD3 
are reduced in E2-induced breast tumors and in E2-exposed breast tissue in experimental 
animals, and increased by antioxidants (49). In this present study we wanted to delineate 
the mechanism by which Res-analogs, TIMBD and HPIMBD act as potent antioxidants 
in breast cancer and examined their effects on the expression levels of SOD3. In this 
regard, we have shown that mRNA and protein expression levels of SOD3 are reduced in 
E2-treated MCF-10A cells, and significantly increased by TIMBD (Figure 26 A, B & C), 
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HPIMBD (Figure 27 A, B & C) as well as prototypic antioxidants Res and  VC ( Figure 
25 C & 25 D ). Furthermore, we have shown that our Res-analogs are better than Res in 
up-regulation of SOD3 mRNA and protein expression levels (Figure 27 7 Figure 27). 
NAD(P)H-quinone oxidoreductase 1 (NQO1) is another very important and well studied 
phase-II detoxifying enzyme that has been recently shown to play important role in E2-
induced breast cancer (36). NQO1 is a key enzyme which converts E2-quinones to E2-
catechols and thus reduces oxidative stress generated by E2-metabolism and subsequent 
carcinogenic process. It has been reported that NQO1 plays important role in chemical-
induced cancer (147-149). Recent work from our laboratory has shown E2-mediated 
decrease in the expression of NQO1 mRNA and protein which was reversed by 
antioxidants or Res in female ACI rats (36), which further supports the importance of 
antioxidant phase-II detoxifying enzyme NQO1 in prevention of breast cancer. In the 
present study, we examined the role of TIMBD and HPIMBD in mediating antioxidant 
defense through regulation of NQO1. We have demonstrated that suppression of NQO1 
mRNA and protein expression levels following E2 treatment can be reversed upon co-
treatment with Res-analogs TIMBD (Figure 28), HPIMBD (Figure 29) as well as 
prototypic antioxidants VC or Res (Figure 25 A & 25 B). Furthermore, we have shown 
that TIMBD-treatment mediated highest induction of NQO1 mRNA and protein 
expression levels (Figure 28). Collectively, these results demonstrate protective role of 
Res-analogs, TIMBD and HPIMBD in E2-induced breast cancer as potent antioxidants.  
In summary, we have presented evidence that our novel Res-analogs TIMBD and 
HPIMBD inhibit proliferation in breast cancer cells  better than resveratrol and have no 
effect on non-tumorigenic breast epithelial cells. These Res-analogs are more potent to 
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mediate antioxidant defense by reducing ROS production, oxidative DNA damage and 
inducing phase-II detoxifying enzymes SOD3 (specific one from superoxide dismutase 
family) and NQO1 in E2-induced breast cancer and may play important roles in the 
regulation of cellular adaptive antioxidant responses against E2-induced breast cancer.  
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CHAPTER 4  
 
DETERMINATION OF THE MECHANISM OF INHIBITION OF E2-INDUCED 
BREAST CANCER BY RES-ANALOGS THROUGH REGULATION OF CNC-B ZIP 
TRANSCRIPTION FACTORS (NRFS) 
 
4.1. Introduction 
      Transcription factors from Cap’n’collar (CNC) family of proteins are well known 
among vertebrates for mediating important developmental and homeostatic functions 
(150-153). The vertebrate nuclear factor erythroid 2-related factor 1 (Nrf1, also called 
NFE2L1), nuclear factor erythroid 2-related factor 2 (Nrf2), and nuclear factor erythroid 
2-related factor 3 (Nrf3) comprise a subgroup of CNC factors that mediate adaptive 
responses to cellular stresses (150-153). The most studied stress-activated CNC factor is 
Nrf2, which is responsible for the transcriptional response of cells to oxidative stress 
mediators and electrophilic xenobiotics (154-158). The three Nrfs have broad and partly 
overlapping expression patterns and functions as stress-activated transcription factors. 
Although, functions of Nrf2 in controlling oxidative stress have been studied, there are 
fewer studies reporting functions of Nrf1 in controlling oxidative stress and estrogen-
induced breast cancer. It has been suggested that Nrf1 may play as important a role in 
human carcinogenesis as Nrf2 (159-162). The transcription factor Nrf2 is known to be 
under homeostatic control by interaction with Kelch-like ECH-associated protein 1 
(Keap1) which favors its rapid ubiquitination and degradation by the proteasome (154, 
155). When the cell encounters oxidative stress, the Keap1-mediated proteasomal 
74 
 
degradation of Nrf2 is compromised allowing Nrf2 to dissociate from Keap1 and 
translocate to the nucleus to activate antioxidant gene expressions (158). Studies have 
shown that homeostatic Keap1-Nrf2 interactions are not permanent and take place in the 
nucleus via shuttling of Keap1 into that compartment (154, 158). In contrast, Nrf1 is not 
regulated by Keap1 instead, the activity of Nrf1 appears to be negatively controlled by its 
N-terminal domain (NTD), which directs Nrf1 to the endoplasmic reticulum (163). Nrf1, 
but not Nrf2 or Nrf3, is essential for embryonic development; Nrf1-/- mice die at mid-late 
gestation, presumably due to anemia-induced hypoxia (153). In contrast, Nrf3 is known 
to negatively regulate antioxidant enzymes (164). 
 
Since Nrf1, Nrf2 and Nrf3 control phase II detoxification enzymes that help in 
detoxification of potential carcinogens, understanding the mechanisms of regulation of 
these three “Nrfs” may help in the development of cancer therapeutics. Further, due to the 
cytoprotective nature of phase II enzymes against oxidative stress-induced diseases 
including cancer, manipulation of the upstream transcription factors controlling these 
factors (e.g., Nrf1, Nrf2 and Nrf3) or enzymes superoxide dismutases 1, 2, 3 (SOD1, 
SOD2, SOD3) and NAD(P)H-quinone oxidoreductase 1 (NQO1) could be useful in the 
search of therapeutic targets against estrogen- induced breast cancer. We report in this 
study that natural antioxidants Res and  and our novel Res-analogs TIMBD and HPIMBD 
may mediate their protective role in E2-induced breast cancer through a complex 
interplay of CNC b-zip family of proteins. 
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4.2 Results 
4.2.1. Estrogen decreases, whereas antioxidants reverse E2-mediated decrease in 
Nrf2 mRNA and protein expression levels, and further increase its mRNA and 
protein expression levels.  
A dose-dependent change in Nrf2 mRNA and protein expression levels was 
determined using different concentrations of E2. A maximum decrease in Nrf2 mRNA 
(24 hour) and protein expression (48 hour) at a dose of 50 nM E2 was observed (Figure 
30 A & 30 B). A time-dependent change in Nrf2 mRNA and protein expression levels 
was determined using 50 nM E2. A maximal inhibition of Nrf2 mRNA expression at 24 
hour and protein expression at 48 hour was observed (Figure 30 C & 30 D). The effect of 
Res and VC on the regulation of Nrf2 mRNA and protein expression levels in MCF-10A 
cells was examined. Vitamin C (1 mM) or  Res (50 μM) significantly reversed E2-
mediated decrease in Nrf2 mRNA and protein expression levels and further increased 
Nrf2 mRNA and protein expression levels in MCF-10A cells after 48 hour of treatment 
(Figure 30 E & 30 F). The fold changes in Nrf2 protein expression levels in MCF-10A 
cells treated with E2, Res, Res + E2,  VC and  VC + E2 for 48 hour were 0.43, 2.33, 1.87, 
3.32 and 2.84, respectively, compared to vehicle-treated control cells (Figure 30 F).  
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Figure 30: 17 β-Estradiol (E2) down-regulates, whereas antioxidants reverse E2-
mediated decrease in Nrf2 mRNA and protein expression levels, and further increase its 
mRNA and protein expression levels in MCF-10A cells. (A) Nrf2 mRNA expression 
levels in MCF-10A cells treated with 10, 50 and 100 nM E2 for 24 hour; (B) Nrf2 protein 
expression levels in MCF-10A cells treated with increased doses of E2 for 48 hour; (C) 
Nrf2 mRNA expression levels in MCF-10A cell line treated with 50 nM E2 for upto 72 
hour; (D) Nrf2 protein expression levels in MCF-10A cell line treated with 50 nM E2 for 
upto 72 hour; (E) Antioxidants (VC and Res) significantly reverse E2-mediated decrease 
in Nrf2 mRNA and expression levels in MCF-10A cells; cells were treated with 50 nM 
E2, 50 µM Res, Res + E2, 1 mM VC or VC + E2 for 24 hour; and (F) Nrf2 protein 
expression levels in MCF-10A cell line treated with 50 nM E2, 50 µM Res, Res + E2, 1 
mM VC or VC + E2 for upto 48 hour.  
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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4.2.2. Estrogen treatment induces Nrf3 and Nrf1, whereas antioxidants differentially 
regulate Nrf3 and Nrf1 in MCF-10A cells.  
Nrf3 mRNA and protein expression levels were quantified in MCF-10A cells 
treated with E2 (50 nM) for upto 72 hour. A significant increase in Nrf3 mRNA as well 
as protein expression levels compared to control was identified at 48 hour after treatment 
(Figure 31 A & 31 B). Resveratrol (50 μM) and  VC (1 mM) treatment reversed E2-
mediated increase in Nrf3 mRNA as well as protein expression levels, and significantly 
decreased Nrf3 mRNA and protein expression levels in MCF-10A cells compared to 
controls (Figure 31 A & 31 B). The fold changes in Nrf3 protein expression levels in 
MCF-10A cells treated with E2, Res, Res + E2,  VC and  VC + E2 for 48 hour were 2.68, 
0.53, 0.31, 0.61 and 0.78, respectively, compared to vehicle-treated control cells (Figure 
31 B). Nrf1 mRNA and protein expression levels were quantified in MCF-10A cells 
treated with E2 (50 nM) for upto 48 hour. A significant increase in Nrf1 mRNA as well 
as protein expression levels compared to control was detected (Figure 31 C & 31 D). 
Antioxidants by themselves also significantly increased Nrf1 mRNA and protein 
expression levels compared to vehicle-treated control cells (Figure 31 C & 31 D). This 
increase was independent of E2 treatment. The fold change in Nrf1 protein expression 
levels in MCF-10A cells treated with E2, Res, Res + E2,  VC and VC + E2 for upto 48 
hour were 2.87, 2.51, 2.62, 2.13 and 1.97, respectively, compared to vehicle-treated 
control cells (Figure 31 D).  
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Figure 31: 17 β-Estradiol induces Nrf3 as well as Nrf1 mRNA and protein expression 
levels in MCF-10A cells. Antioxidants (VC and Res) reverse E2-mediated increase in 
Nrf3 mRNA and protein expression levels and induce Nrf1 mRNA and protein 
expression levels in MCF-10A cells. (A) Nrf3 mRNA expression levels in MCF-10A 
cells treated with 50 nM E2, 50 µM Res, Res + E2, 1 mM VC or VC + E2  for upto 72 
hour;  (B) Nrf3 protein expression levels in MCF-10A cells treated with 50 nM E2 and 50 
μM Res, Res + E2, 1 mM VC  or VC + E2  for 48 hour; (C) Nrf1 mRNA expression 
levels in MCF-10A cells treated with 50 nM E2, 50 μM Res, Res + E2, 1 mM VC or VC 
+ E2 for upto 48 hour; and (D) Nrf1 protein expression levels in MCF-10A cells treated 
with 50 nM E2, 50 μM Res, Res + E2, 1 mM VC or VC + E2  for 48 hour. 
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4.2.3. Nrf3 negatively regulates Nrf2 and Nrf2-dependent gene NQO1   
Nrf2 is a known positive regulator of antioxidant phase-II detoxifying gene 
NQO1 (36), whereas Nrf3 is known to negatively regulate NQO1 gene (164). We 
investigated whether silencing of Nrf3 has any effect on the expression of Nrf2 gene. An 
increase in Nrf2 protein expression was observed after silencing of Nrf3 in MCF-10A 
cells (Figure 32). Additionally an increase in NQO1 protein expression after silencing of 
Nrf3 was detected (Figure 32).  
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Figure 32: Nrf3 negatively regulates Nrf2 and Nrf2-dependent gene NQO1. MCF-10A 
cells were transfected with 20 nmol/l of scrambled siRNA or siNrf3 for 48 hour, and 
Western blot analysis was carried out using Nrf3 antibody. The same membrane was 
reprobed with Nrf2, NQO1 and α-tubulin antibodies. 
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4.2.4. Nrf3 interacts with Nrf2.  
Co-immunoprecipitation is an in vitro method for detecting protein-protein 
interactions. We used Pierce Co-immunoprecipitation Kit to investigate whether Nrf2 
interacts with Nrf3 and vice versa as described in the methods section. After 
immobilization and immunoprecipitation of the primary antibody (Nrf2), Co-Ip of 
interacting protein Nrf3 was detected by western blotting (Figure 33 i). The same blot 
was stripped and probed for Nrf2 and a mild band was detected (Figure 33 ii). After 
immobilization and immunoprecipitation of the primary antibody (Nrf3), Co-Ip of 
interacting protein Nrf2 was detected by Western blotting (Figure 33 iii). The same blot 
was stripped and probed for Nrf3 and Nrf3 was detected (Figure 33 iv). Any unspecific 
interactions were identified by using the provided control gel and substituting IgG for the 
specific antibody. No nonspecific interaction was observed (Figure 33).  
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Figure 33: Co-Immunoprecipitation of Nrf2 and Nrf3 from MCF-10A cells. Co- 
Immunoprecipitation of Nrf2 and Nrf3 were performed in MCF-10A cell lysates using 
Pierce Co-Ip kit, according to manufactures protocol with some modifications.  The 
immunoblot in the upper panel in figure 33 (i) was probed for Nrf3 after Nrf2 was pulled 
down. The same blot was stripped and probed for Nrf2 shown in the lower panel of figure 
33 (ii).  The immunoblot in the upper panel in figure 33 (iii) was probed for Nrf2 after 
Nrf3 was pulled down. The same blot was stripped and probed for Nrf3 shown in the 
lower panel of figure 33 (iv). 
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4.2.5. Res-analogs significantly induce Nrf2 total mRNA and protein. 
The effects of TIMBD and HPIMBD on the regulation of Nrf2 mRNA and 
protein expression levels in MCF-10A cells were examined. 50 μM concentrations of 
TIMBD significantly increased Nrf2 mRNA (Figure 34 A) expression levels at 24 hour; 
and Nrf2 protein (Figure 34 B) expression levels at 48 hour in MCF-10A cells. 50 μM 
concentrations of HPIMBD also significantly increased Nrf2 mRNA (Figure 34 D) 
expression levels at 24 hour; and Nrf2 protein (Figure 34 E) expression levels at 48 hour 
in MCF-10A cells. The fold changes in Nrf2 protein expression levels in MCF-10A cells 
treated with 50 nM E2, 50 μM Res and 50 μM TIMBD for 48 hour were 0.52, 2.33, and 
3.97, respectively, compared to vehicle-treated control cells (Figure 34 C). The fold 
changes in Nrf2 protein expression levels in MCF-10A cells treated with 50 nM E2, 50 
μM Res and 50 μM HIMBD for 48 hour were 0.52, 2.33, and 3.24, respectively, 
compared to vehicle-treated control cells (Figure 34 F).  
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Figure 34: 17 β-Estradiol (E2) down-regulates, whereas Res-analogs reverse E2-
mediated decrease in Nrf2 mRNA and protein expression levels, and further increase its 
mRNA and protein expression levels in MCF-10A cells. (A) Nrf2 mRNA expression 
levels in MCF-10A cell line treated with 50 nM E2,  50 µM Res or 50 µM TIMBD for 24 
hour; (B) Representative Western blot showing up-regulation of Nrf2 protein expression 
levels in MCF-10A cells treated with 50 nM E2,  50 µM Res or 50 µM TIMBD for upto 
48 hour; (C) Relative Nrf2 protein expression levels in MCF-10A cell line treated with 50 
nM E2, 50 µM Res or 50 µM TIMBD for upto 48 hour; (D) Nrf2 mRNA expression 
levels in MCF-10A cell line treated with 50 nM E2,  50 µM Res or 50 µM HPIMBD for 
24 hour; (E) Representative Western blot showing up-regulation of Nrf2 protein 
expression levels in MCF-10A cells treated with 50 nM E2,  50 µM Res or 50 µM 
HPIMBD for upto 48 hour; and (F) Relative Nrf2 protein expression levels in MCF-10A 
cell line treated with 50 nM E2, 50 µM Res or 50 µM HPIMBD for upto 48 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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4.2.6. Res-analogs reverse E2-mediated up-regulation of Nrf3 mRNA and protein. 
The effects of TIMBD and HPIMBD on the regulation of Nrf3 mRNA and 
protein expression levels in MCF-10A cells were examined. MCF-10A cells were treated 
with E2 (50 nM), 50 μM of Res, TIMBD or HPIMBD for upto 72 hour. Treatment with 
E2 significantly increased Nrf3 mRNA expression levels at 48 hour and protein 
expression levels at 72 hour, compared to control (Figure 35 A & 35 B). Treatment with 
TIMBD reversed E2-mediated increase in Nrf3 mRNA (Figure 35 A) as well as protein 
expression levels (Figure 35 B), and significantly decreased Nrf3 mRNA and protein 
expression levels in MCF-10A cells compared to controls (Figure 35 A & 35 B). 
Treatment with HPIMBD also reversed E2-mediated increase in Nrf3 mRNA (Figure 35 
D) as well as protein expression levels (Figure 35 E), and significantly decreased Nrf3 
mRNA and protein expression levels in MCF-10A cells compared to controls (Figure 35 
D & 35 E). Resveratrol-mediated decrease in Nrf3 mRNA (Figure 35 A & 35 D) and 
protein (Figure 35 C & 35 F) expression levels at 24 hour time point was not noticed at 
48 hour time point, where as TIMBD and HPIMBD-mediated decrease in Nrf3 protein 
expression was significant at 48 hour as compared to control. The fold changes in Nrf3 
protein expression levels in MCF-10A cells treated with E2, Res or TIMBD for 48 hour 
were 2.93, 0.89 and 0.33 respectively, compared to vehicle-treated control cells (Figure 
35 C). The fold changes in Nrf3 protein expression levels in MCF-10A cells treated with 
E2, Res or HPIMBD for 48 hour were 2.93, 0.89 and 0.41 respectively, compared to 
vehicle-treated control cells (Figure 35 F). 
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Figure 35: 17 β-Estradiol induces Nrf3 mRNA and protein expression levels in MCF-
10A cells. Res-analogs, TIMBD or HPIMBD reverse E2-mediated increase in Nrf3 
mRNA and protein expression levels in MCF-10A cells. (A) Nrf3 mRNA expression 
levels in MCF-10A cells treated with 50 nM E2,  50 µM Res or 50 µM TIMBD for upto 
48 hour; (B) Representative Western blot showing reversal of E2-mediated up-regulation 
of Nrf3 protein expression levels in MCF-10A cells treated with 50 nM E2,  50 µM Res 
or 50 µM TIMBD for upto 48 hour; (C) Relative Nrf3 protein expression levels in MCF-
10A cells treated with 50 nM E2, 50 µM Res or 50 µM TIMBD for upto 72 hour; (D) 
Nrf3 mRNA expression levels in MCF-10A cells treated with 50 nM E2,  50 µM Res or 
50 µM HPIMBD for upto 48 hour; (E) Representative western blot showing reversal of 
E2-mediated up-regulation of Nrf3 protein expression levels in MCF-10A cells treated 
with 50 nM E2,  50 µM Res or 50 µM HPIMBD for upto 48 hour; and (F) Relative Nrf3 
protein expression levels in MCF-10A cell line treated with 50 nM E2, 50 µM Res or 50 
µM HPIMBD for upto 72 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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4.2.7. Res-analogs up-regulate Nrf1 mRNA and protein in MCF-10A cells. 
Nrf1 mRNA and protein expression levels were quantified in MCF-10A cells 
treated with E2 (50 nM) for upto 72 hour. A significant increase in Nrf1 mRNA as well 
as protein expression levels compared to control was detected (Figure 36 A & 36 B). 
Resveratrol-analog HPIMBD by itself significantly increased Nrf1 mRNA and protein 
expression levels compared to vehicle-treated control cells (Figure 36 A & 36 B). 
Resveratrol-analog TIMBD also by itself significantly increased Nrf1 mRNA and protein 
expression levels compared to vehicle-treated control cells (Figure 36 D & 36 E). This 
increase of Nrf1 was independent of E2 treatment. The fold changes in Nrf1 protein 
expression levels in MCF-10A cells treated with E2, Res and HPIMBD for 24 hour were 
3.13, 2.73, and 2.88, respectively, compared to vehicle-treated control cells (Figure 36 
C). The fold changes in Nrf1 protein expression levels in MCF-10A cells treated with E2, 
Res and TIMBD for 24 hour were 3.10, 2.62, and 2.95, respectively, compared to 
vehicle-treated control cells (Figure 36 F). 
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Figure 36: 17 β-Estradiol induces Nrf1 mRNA and protein expression levels in MCF-
10A cells. Res-analogs, TIMBD or HPIMBD induce Nrf1 mRNA and protein expression 
levels in MCF-10A cells. (A) Nrf1 mRNA expression levels in MCF-10A cells treated 
with 50 nM E2,  50 µM Res or 50 µM HPIMBD for 24 hour; (B) Representative western 
blot showing up-regulation of Nrf1 protein expression levels in MCF-10A cells treated 
with 50 nM E2,  50 µM Res or 50 µM HPIMBD for 24 hour; (C) Relative Nrf1 protein 
expression levels in MCF-10A cells treated with 50 nM E2, 50 µM Res or 50 µM 
HPIMBD for upto 72 hour; (D) Nrf1 mRNA expression levels in MCF-10A cells treated 
with 50 nM E2,  50 µM Res or 50 µM TIMBD for 24 hour; (E) Representative western 
blot showing up-regulation of Nrf1 protein expression levels in MCF-10A cells treated 
with 50 nM E2,  50 µM Res or 50 µM TIMBD for 24 hour; and (F) Relative Nrf1 protein 
expression levels in MCF-10A cell line treated with 50 nM E2, 50 µM Res or 50 µM 
TIMBD for upto 72  hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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4.3  Discussion: 
Cap’n’collar (CNC) basic leucine zipper transcription factors are well known for 
their crucial roles in regulation of mammalian genes involved in developmental and 
homeostatic processes (150-153). Among the vertebrate CNC family of proteins, the 
most studied transcription factors are Nuclear factor erythroid 2-related factor 1 (Nrf1, 
also called NFE2L1), nuclear factor erythroid 2-related factor 2 (Nrf2), and nuclear factor 
erythroid 2-related factor 3 (Nrf3), known for their crucial roles in providing adaptive 
responses to cellular stresses (150-153). The most extensively explored CNC family of 
transcription factor is Nrf2 which regulates expressions of genes in response to elevated 
cellular oxidative stress and keeps the mediators of oxidative stress in control (154). In 
presence of oxidative stress mediators when reactive oxygen species (ROS) are produced 
in the cells, as a defense response to prevent excessive ROS mediated damages and keep 
the oxidative stress in check, Nrf2 levels are elevated. The nuclear factor erythroid 2-
related factor (Nrf2) is a master regulator which is responsible for transcriptional 
activation of a variety of antioxidant genes and phase-II detoxifying enzymes. These 
antioxidant genes in turn bring back cellular redox homeostasis. Under normal cellular 
conditions when no oxidative stress is encounterd, Nrf2 remains sequestered in the 
cytosol by an adaptor protein named Kelch-like ECH-associated protein 1 (Keap1). Keap 
1 is cysteine-rich protein that acts as a negative regulator of Nrf2 by interacting to it and 
keeping it sequestered in the cytosol. Under normal conditions Keap1 mediates rapid 
proteasomal-degradation of Nrf2 as a result of its ubiquitination and maintains the 
cellular base level of Nrf2 (158). When oxidative stress is encountered, cysteine residues 
of Keap1 act as sensor and detect changes in cellular redox state. Under such 
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circumstances Keap1 fails to bind to Nrf2 and promote its proteasomal-degradation. As a 
result, unbound and free Nrf2 gets dissociated from its negative counterpart Keap 1 and 
translocates to the nucleus to turn on antioxidant gene expressions (155). This interaction 
between Keap1 and Nrf2 is not steady, it takes place only when there is an elevated 
oxidative stress encountered in the cell and this interaction takes place inside the nucleus 
after Keap1 is shuttled in (155). Inside the nucleus Nrf2 forms heterodimer by binding to 
small Maf proteins and this heterodymeric form binds to the antioxidant response 
elements (ARE) of the DNA of antioxidant and Phase-II detoxifying genes resulting in 
their transcriptional activation.  
The Nrf2 signaling pathway is responsible for mediating cellular defense against 
oxidative burden and a variety of detoxifying and cytoprotective genes are regulated by 
this master transcription factor (158). Different antioxidant proteins and Phase-II 
detoxifying enzymes that play key roles in scavenging excessive ROS production and 
provide cellular defense against oxidative damage to the cell includes superoxide 
dismutases, glutathione peroxidase, heme oxygenase, flavin containing monooxygenase 
1, NQO1 etc (36, 49, 165-167). Recent studies from our laboratory and that of others 
have shown critical role of Nrf2 in E2-induced breast carcinogenesis (167-170). Since 
Nrf2 regulates several antioxidant enzymes and our Res-analogs TIMBD and HPIMBD 
have shown to significantly up-regulate Phase-II detoxifying enzymes SOD3 and NQO1, 
we wanted to examine if our novel Res-analogs also regulate Nrf2 expression in breast 
epithelial cells. In this study we found significant suppression of Nrf2 mRNA and protein 
expression levels in E2-treated MCF-10A cells (Figure 30 A-D). This suppression was 
reversed and further increased upon co-treatment with prototypic antioxidants Res or VC 
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(Figure 30E & 30 F), or Res-analogs (Figure 34). Treatment with TIMBD significantly 
increased the mRNA and protein expression levels of Nrf2 better than Res (Figure 34 A 
& 34 B). Treatment with HPIMBD also significantly increased the mRNA and protein 
expression levels of Nrf2 (Figure 34 D & 34 E). These findings suggested that Res, 
TIMBD and HPIMBD regulate E2-induced breast cancer via Nrf2-dependant signaling 
pathway.  
Nuclear factor erythroid 2-related factor 1 (Nrf1, also called NFE2L1) is another 
member of CNC b-zip protein family. Nrf1 is well known to regulate expression of 
cytoprotective genes through binding to the antioxidant-response elements in the 
promoter regions of these genes (159, 160). Examples of cytoprotective genes those are 
transcribed by Nrf1 include NAD(P)H:quinone oxidoreductase-1 (NQO1), Heme 
Oxygenase 1 (HMOX-1), Metallothionein, Ferritin etc (152, 153). The well studied 
functions of Nrf1 include prevention of oxidative stress, prevention of metal-induced 
toxicity and induction of anti-apoptotic genes from bcl2 family (159, 162). Nrf1 is 
suggested to play critical role in embryonic development; it has been shown that Nrf1-/- 
mice die prematurely due to anemia (153). But unlike Nrf2, Nrf1 is not that well studied 
for its role in prevention of oxidative stress and estrogen-induced breast cancer. Thus in 
this study we wanted to examine the role of Nrf1 in prevention of E2-induced breast 
cancer and the effects of Res, and Res-analogs in its regulation. We found significant 
increase in Nrf1 mRNA and protein expression following E2 treatment in MCF-10A cells 
(Figure 31 C & 31 D). Treatment with Res or VC (Figure 31 C & 31 D), or Res-analogs 
(Figure 36) also increased Nrf1 mRNA and protein expression levels. From these results 
it could be suggested that Nrf1 has compensatory role in E2-induced stress and Res; 
97 
 
TIMBD and HPIMBD play chemopreventive role in E2-induced breast cancer by up-
regulation of cytoprotective gene Nrf1. Nevertheless, more studies are needed to be done 
to show specific role of Nrf1 in E2-induced breast cancer. 
Nuclear factor erythroid-derived 2-like 3 (Nrf3) is also a CNC-bZIP transcription 
factor (150, 152). It is suggested that Nrf3 plays important role in a variety of cellular 
processes including. inflammation, differentiation and carcinogenesis. Till date there is 
no study suggesting important role of Nrf3 in E2-induced breast cancer. In this study we 
examined the role of Nrf3 in E2-induced breast cancer and the effect of prototypic 
antioxidants Res, and Res-analogs TIMBD and HPIMBD in regulation of Nrf3. We 
found that E2 treatment increased Nrf3 mRNA and protein expression levels in a time 
dependant manner in MCF-10A cells (Figure 31 A & 31 B). Estrogen-mediated increase 
in the expression of Nrf3 mRNA and protein was reversed by antioxidants VC or Res 
(Figure 31 A & 31 B). This Estrogen-mediated increase in Nrf3 mRNA and protein levels 
was also reversed by our novel Res-analogs (Figure 35). These results further support the 
importance of Nrf3 in E2-induced breast cancer. These results suggest that since Nrf3 is a 
negative regulator of antioxidant response, VC-, Res- or Res-analogs-mediated 
suppression of Nrf3 may protect the cellular phase-II detoxifying enzymes and mediate 
protection to the normal breast tissue from carcinogenic insult by E2.   
The three Nrfs have broad and partly overlapping expression patterns and 
functions as stress-activated transcription factors. Nrf3 is the third member of the Nrf 
gene family (152). Nrf3 is known to repress NQO1 gene expression and to negatively 
regulate antioxidant response (164). In order to better understand the mechanisms by 
which Nrf3 regulated in E2-induced breast cancer we examined the possible relationship 
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between Nrf2 and Nrf3. The co-existence of Nrf3 with Nrf2 shown by Co-Ip assay and 
the increased expression of Nrf2 and NQO1 following silencing of Nrf3 suggests that 
probably Nrf2 is regulated by Nrf3 (171). Further studies are needed to be done to 
establish this relationship between Nrf2 and Nrf3. 
Since Nrf1, Nrf2 and Nrf3 control phase II detoxification enzymes that help in 
detoxification of potential carcinogens, understanding the mechanisms of regulation of 
these three “Nrfs” may help in the development of cancer therapeutics. We report in this 
study that antioxidants mediate their protective role in E2-induced breast cancer through 
a complex interplay of CNC b-zip family of proteins. 
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CHAPTER 5  
 
DETERMINATION OF THE ROLE OF RES-ANALOGS IN EPITHELIAL-
MESENCHYMAL TRANSITION (EMT) IN BREAST CANCER 
 
5.1. Introduction 
Epithelial–mesenchymal transition (EMT) is a biological process which allows 
epithelial cells to undergo various molecular changes and to assume mesenchymal-like 
phenotype (172). This process results in changes in functional characteristics of the cells 
which become more migratory type (mesenchymal) than that of polarized type epithelial 
cells likely to interact with the basement membrane (172). Epithelial–mesenchymal 
transition is a key step during embryogenesis and also implicated in tissue regeneration 
(173). But an excess of epithelial cell proliferation and migration has fatal consequences 
of cancer metastasis (173). Following transformation to mesenchymal phenotype, the 
epithelial cancer cells acquire migratory and invasive properties, invade through the 
basement membrane, and eventually metastasize with life-threatening consequences. 
Determination of molecular, biochemical, genetic and epigenetic basis of EMT and 
cancer metastasis has been very active field of research (174). A number of these studies 
suggest that activation of an EMT program is a critical mechanism for the transformation 
of epithelial cancers to malignant and metastatic types (175). One of the most common 
epithelial cancers are breast cancers, breast cancer metastasis is also largely known to be 
consequences of the EMT program (176). The molecular mechanism of EMT has been 
well characterized (177-179). One most important characteristic molecular feature of 
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EMT is decrease in the expression of epithelial cell marker, E-cadherin. E-cadherin is a 
transmembrane protein that plays very important role in cell adhesion, cell-cell and cell-
matrix interactions (180). Decreased E-cadherin expression in epithelial tumor cells 
implies onset of metastasis (181). Without E-cadherin the cells lose their epithelial 
characteristics. Like other cancers, breast carcinogenesis is also associated with the 
decreased function and expression levels of E-cadherin (182). At the molecular level, E-
cadherin expression is controlled by quite a few transcription factors related to the 
process of EMT, like, snail, slug, zeb 1, and zeb 2 (183, 184). These transcription 
repressors of E-cadherin have traditionally been implicated in promoting EMT.  
Different studies are suggestive of the fact that E-cadherin is an invasive 
suppressor and its loss of expression is associated with poor prognosis in breast cancer. 
Thus, targeting inhibition of the process of EMT program may help in developing 
strategy for the prevention of breast cancer cell metastasis. Resveratrol has been well 
recognized as a potential cancer chemopreventive agent. The potential role of Res in 
inhibition of EMT in breast cancer has been well established (185). Resveratrol 
suppresses EMT by modulating different signaling pathways (185, 186). As discussed 
before in chapter-3, in spite of being potent anti-tumorigenic agent in vitro, Res has its 
own limitations of poor efficacy in human body that stops it to be used as a preferable 
drug of cancer chemotherapy. Thus, to improve the anticancer efficacy of Res, we have 
synthesized aza-resveratrol analogs: TIMBD and HPIMBD. Our previous studies as 
discussed in the previous chapters, demonstrate that the novel Res-analogs inhibit the 
growth of different human cancer cells and have no toxicity towards non-tumorigenic 
human breast epithelial cells. However, the effects of TIMBD and HPIMBD on the 
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metastasis of breast cancer cells have not been elucidated. To address this issue, we 
initially assessed the expression profiles of EMT-related markers in very aggressive 
metastatic breast cancer cells, MDA-MB-231 after treatment with Res, TIMBD or 
HPIMBD. 
Matrix metalloproteinases (MMPs) are enzymes that break down and modify the 
extracellular matrix resulting in decreased cell-cell and cell-matrix contacts (187). As a 
consequence, epithelial cells get detached from the surrounding tissue and metastasize 
(187). MMPs are well known to play key role in embryonic development and organ 
morphogenesis (188, 189).  Recent studies suggest that MMPs also play important role in 
cancer metastasis (190). MMPs are frequently found to be up regulated in breast cancer, 
facilitating tumorigenesis, cancer cell invasion and migration (191). In this current study, 
we have examined the regulation of MMPs by Res-analogs in metastatic breast cancer 
cells.  
Our study demonstrated that Res-analogs TIMBD and HPIMBD are more 
effective than the parent compound Res in inducing E-cadherin and down-regulation of 
EMT-inducers: MMPs, Snail, Slug and Zeb1. All these changes in molecular markers of 
EMT imply inhibition of EMT. Furthermore, we have demonstrated that our Res-analogs 
are very potent to inhibit the migratory properties of MDA-MB-231 cells by performing 
wound healing assay. To further delineate the mechanism of action of Res-analogs in 
inhibition of the process of EMT, we found involvement of wnt/-catenin signaling 
pathway which is implicated to drive the process of EMT in carcinogenesis. Our results 
demonstrate the potential of our novel Res-analogs in preventing the EMT-induced 
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malignant transformation of breast carcinoma through modulation of wnt/-catenin 
pathway.  
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5.2. Results 
5.2.1. Res-analogs down regulate Matrix metallo proteinases (MMPs) in metastatic 
breast cancer cells. 
Matrix metallo proteinases (MMPs) are very important enzymes responsible for 
extracellular matrix (ECM) breakdown and remodeling of epithelial mesenchyme.  ECM 
breakdown is the ultimate step leading towards invasion, migration and metastasis of 
cancer cells. In this study, we have examined the protecting effects of Res, TIMBD and 
HPIMBD against breast cancer metastasis. We have tested the effects of our Res-analogs 
in the protein expression levels of MMP2, MMP3 and MMP9 in metastatic breast cancer 
cells, MDA-MB-231, treated for upto 48 hour. TIMBD inhibited MMP 2, -3, and -9 
significantly (Figure 37 A). TIMBD, but not Res, inhibited the protein expression levels 
of MMP 2 and -9 in MDA-MB-231 cells at its IC50 dose (21µM) (Figure 37 A). 
HPIMBD, on the other hand, inhibited the protein expression levels of MMP 3 and -9; 
but not MMP 2 in MDA-MB-231 cells at its IC50 dose (29 µM) (Figure 37 B). 
Resveratrol was only able to down regulate MMP 3 at its IC50 dose (66 µM) (Figure 37 A 
& 37 B).  
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Figure 37: Res-analogs, TIMBD and HPIMBD down-regulate matrix metallo proteinases 
(MMPs) in metastatic breast cancer cells, MDA-MB-231. (A) Representative western 
blot showing protein expression levels of MMP 3, MMP 2 and MMP 9 in MDA-MB-231 
cells treated with IC50 doses of Res (66 µM ) or TIMBD (21µM) for upto 48 hour. (B) 
Representative Western blot showing protein expression levels of MMP 3, MMP 2 and 
MMP 9 in MDA-MB-231 cells treated with IC50 doses of Res (66 µM ) or HPIMBD (29 
µM) for upto 48 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
 
 
 
 
 
(A) (B) 
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5.2.2. Mechanism of inhibition of EMT by Res-analogs in metastatic breast cancer 
cells. 
To elucidate the role of Res-analogs in the EMT program of breast 
carcinogenesis, we  examined the effect of the Res-analogs TIMBD and HPIMBD on the 
expression of EMT-representative markers in MDA-MB-231 metastatic breast cancer 
cells by Western blot analysis and compared these effects with the parent compound Res. 
Our results demonstrate that at their IC50 concentrations of 66 μM, 29 μM and 21 μM, 
respectively for Res, HPIMBD and TIMBD, resulted in an elevated expression of 
epithelial marker E-cadherin, and consequently repressing the expression of 
mesenchymal-related markers snail, slug and zeb1 (Figure 38 A & 38 B). However, Res, 
TIMBD and HPIMBD had no effects on the expression level of mesenchymal-related 
marker zeb 2 (Figure 38 A & 38 B). Our results show that TIMBD and HPIMBD were 
better effective than Res in up-regulation of E-cadherin; the fold changes in E-cadherin 
protein expression levels in MDA-MB-231 cells treated with Res, TIMBD and HPIMBD 
for 24 hour were 2.12, 3.11 and 2.55 , respectively, compared to vehicle-treated control 
cells (Figure 38 A & 38 B). Among the two Res-analogs, TIMBD was more effective in 
down-regulation of suppressors of E-cadherin; snail and zeb 1. The fold changes in snail 
protein expression levels in MDA-MB-231 cells treated with Res, TIMBD and HPIMBD 
for 24 hour were 0.42, 0.41, 0.53. respectively, compared to vehicle-treated control cells 
(Figure 38 A & 38 B).. The fold changes in zeb 1 protein expression levels in MDA-MB-
231 cells treated with Res, TIMBD and HPIMBD for 24 hour were 0.46, 0.41, 0.45 
respectively, compared to vehicle-treated control cells (Figure 38 A & 38 B). Although 
TIMBD and HPIMBD significantly and effectively down-regulated slug protein 
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expression levels, however, Res-mediated down regulation of slug protein expression was 
better than Res-analogs TIMBD and HPIMBD. The fold changes in slug protein 
expression levels in MDA-MB-231 cells treated with Res, TIMBD and HPIMBD for 24 
hour were 0.27, 0.31 and 0.56, respectively, compared to vehicle-treated control cells 
(Figure 38 A & 38 B).  
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Figure 38: Mechanism of regulation of E-Cadherin by Res-analogs, TIMBD and 
HPIMBD in metastatic breast cancer cells, MDA-MB-231. (A) Representative western 
blot showing significant up-regulation of E-cadherin protein; and down-regulation of 
repressors of E-cadherin: Snail, Slug and Zeb 1 protein expression levels in MDA-MB-
231 cells treated with IC50 doses of Res (66 µM ) or TIMBD (21µM) for upto 48 hour. 
(B) Representative western blot showing significant up-regulation of E-cadherin protein; 
and down-regulation of repressors of E-cadherin: Snail, Slug and Zeb 1 protein 
expression levels in MDA-MB-231 cells treated with IC50 doses of Res (66 µM ) or 
HPIMBD (29µM) for upto 48 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
 
 
 
(A) (B) 
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5.2.3. Res-analogs inhibit EMT through regulation of Wnt/β-catenin pathway in 
breast cancer. 
β-catenin functions as a transcriptional coactivator of the canonical Wnt signaling 
pathway, which contributes to EMT during tumorigenesis (192, 193). The dissociation of 
β-catenin from the cytoplasmic tail of E-cadherin may increase the nonjunctional pool of 
β-catenin in cytosol, thereby leading to epithelial cell migration (194). Therefore, to 
elucidate whether the increase in E-cadherin in response to our novel Res-analogs 
TIMBD and HPIMBD in MDA-MB-231 cells is accompanied by the reconstitution of the 
E-cadherin–β-catenin complex and the suppression of Wnt/β-catenin signaling, the 
expression, cellular distribution, and function of β-catenin were studied. An inhibition of 
β-catenin mRNA levels was observed in the Res-analogs treated MDA-MB-231 cells at a 
dosage of 50 µM (Figure 39 B & 39 C). Consistently, TIMBD and HPIMBD reduced the 
nuclear translocation of β-catenin protein (Figure 41 A & 41 B). In particular, the 
knockdown of β-catenin by specific siRNA converted the expression status of the EMT 
marker E-cadherin in MDA-MB-231 cells compared with that of the scramble siRNA 
control (Figure 42). Subsequently, colony formation assay was performed in MDA-MB-
231 cells transfected with si- β-catenin to determine growth promoting effect of β-
catenin. The results show that si-β-catenin treatment decreased the cancer cell colonies 
suggesting tumorigenic role of β-catenin in metastatic breast cancer cell MDA-MB-231 
(Figure 39 A). Down-regulation of Frizzled-4 mRNA (Figure 39 D & 39 E, and Wnt 7b 
mRNA (Figure 39 F & 39 G) was also observed in MDA-MB-231 cells treated with 50 
µM of Res, HPIMBD or TIMBD for 24 hour. Resveratrol and its analogs significantly 
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up-regulated epithelial tumor suppressor gene Wnt 5a in human breast epithelial cells, 
MCF-10A (Figure 40 A & 40 B). Overall, these results indicate that TIMBD and 
HPIMBD down-regulates the free pool of nuclear β-catenin, suggesting that the 
modulation of Wnt/β-catenin signaling may be a possible mechanism of action through 
which TIMBD and HPIMBD may elicit the EMT reversal of MDA-MB-231 cells. 
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Figure 39: Res-analogs, HPIMBD and TIMBD modulate Wnt/-catenin signaling in 
metastatic breast cancer cells, MDA-MB-231. (A) Colony formation assay showing 
growth promoting effect of -catenin in MDA-MB-231 cells transfected with si--catenin 
with or without E2;   (B) Relative -catenin mRNA expression in MDA-MB-231 cells 
treated with 50 µM Res or 50 µM HPIMBD for 24 hour; (C) Relative -catenin mRNA 
expression in MDA-MB-231 cells treated with 50 µM Res or 50 µM TIMBD for 24 hour; 
(D) Relative Frizzled-4 mRNA expression in MDA-MB-231 cells treated with 50 µM 
Res or 50 µM HPIMBD for 24 hour; (E) Relative Frizzled-4 mRNA expression in MDA-
MB-231 cells treated with 50 µM Res or 50 µM TIMBD for 24 hour; (F) Relative wnt-7b 
mRNA expression in MDA-MB-231 cells treated with 50 µM Res or 50 µM HPIMBD 
for 24 hour; and (G) Relative wnt-7b mRNA expression in MDA-MB-231 cells treated 
with 50 µM Res or 50 µM TIMBD for 24 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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Figure 40: Res-analogs, HPIMBD and TIMBD significantly up-regulate epithelial tumor 
suppressor gene Wnt-5a in human breast epithelial cells, MCF-10A. (A) Relative Wnt-5a 
mRNA expression in MCF-10A cells treated with 50 µM Res or 50 µM HPIMBD for 24 
hour; and (B) Relative Wnt-5a mRNA expression in MCF-10A cells treated with 50 µM 
Res or 50 µM TIMBD for 24 hour. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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5.2.4. Res-analogs inhibit nuclear translocation of β-catenin in breast cancer. 
To examine the effects of TIMBD and HPIMBD in distribution of -catenin 
protein in the breast cancer cells MDA-MB-231, cytoplasmic and nuclear proteins were 
extracted from the MDA-MB-231 cells. The levels of -catenin protein were determined 
by Western blotting of equal amounts of protein from cytoplasmic and nuclear extracts 
from MDA-MD-231 cells treated with 66 µM of Res, 29 µM of HPIMBD and 21 µM of 
TIMBD (IC50 values of these compounds for MDA-MB-231 cells) for 6 hour. More -
catenin was found in the cytoplasmic extracts treated with TIMBD or HPIMBD. In 
contrast, treatment with Res increased nuclear expression of -catenin (Figure 42) in 
MDA-MB-231 cells as compared to cytoplasmic extract. These results suggest that our 
novel Res-analogs TIMBD and HPIMBD are not only capable of down regulation of -
catenin mRNA and protein expression levels, but also they inhibit nuclear translocation 
of -catenin protein in breast cancer cells MDA-MB-231. 
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Figure 41: Res-analogs, TIMBD and HPIMBD inhibit nuclear translocation of β-catenin 
in breast cancer cells, MDA-MB-231. (A) Representative Western blot showing 
decreased expression of -catenin protein levels in the nuclear fractions from MDA-MB-
231 cells treated with 66 µM of Res and 21 µM of TIMBD (IC50 values of these 
compounds for MDA-MB-231 cells) for 6 hour; and (B) Representative Western blot 
showing decreased expression of -catenin protein levels in the nuclear fractions from 
MDA-MB-231 cells treated with 66 µM of Res and 29 µM of HPIMBD (IC50 values of 
these compounds for MDA-MB-231 cells) for 6 hour.  
. 
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 5.2.5. β-catenin is negative regulator of E-cadherin. 
We investigated whether silencing of -catenin has any effect on the expression 
of E-cadherin gene in MDA-MB-231 cells. An increase in E-cadherin protein expression 
was observed after silencing of -catenin in MDA-MB-231 cells using RNA-interference 
technique (Figure 42 A & 42 B). 
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Figure 42: -catenin is negative regulator of E-Cadherin. (A) MDA-MB-231 cells were 
transfected with 15 nmol/l of scrambled siRNA or si -catenin with or without TIMBD 
for 48 hour, and western blot analysis was carried out using -catenin antibody. The same 
membrane was reprobed with E-Cadherin antibody; (B) MDA-MB-231 cells were 
transfected with 15 nmol/l of scrambled siRNA or si -catenin with or without HPIMBD 
for 48 hour, and western blot analysis was carried out using -catenin antibody. The same 
membrane was reprobed with E-Cadherin antibody. 
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 5.2.6. Res-analogs prevent breast cancer cell migration in vitro. 
Considering the ability of our novel Res-analogs in down-regulation of EMT-
specific molecular markers in breast cancer cells, we next evaluated the ability of these 
compounds in controlling migration of these aggressive metastatic breast cancer cells by 
wound healing assay. MDA-MB-231 cells were grown to confluence in six-well culture 
plates and then treated with 50 µM of Res, TIMBD or HPIMBD. Scratches were made 
with a 20 µl pipette tip. It took 24 hour for the wounds to completely close up in 
untreated cells, suggesting that these cells are very aggressive. Resveratrol treatment 
inhibited approximately 30% cell migration at 24 hour time point where wound closure 
was evaluated. Whereas TIMBD or HPIMBD inhibited approximately 50–60% cell 
migration after 24 hour compared to the control cells which had almost completely closed 
the wounds (Figure 43 & Figure 44).  
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Figure 43: Res-analog TIMBD inhibits migration of aggressive breast cancer cells, 
MDA-MB-231 in vitro shown by wound-healing assay. MDA-MB-231 cells were treated 
with 50 nM E2, 50 µM Res or 50 µM TIMBD for 24 hour and wound-healing assays 
were performed as described in the Materials and methods.  
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Figure 44: Res-analog HPIMBD inhibits migration of aggressive breast cancer cells, 
MDA-MB-231 in vitro shown by wound-healing assay. MDA-MB-231 cells were treated 
with 50 nM E2, 50 µM Res or 50 µM HPIMBD for 24 hour and wound-healing assays 
were performed as described in the Materials and methods.  
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5.3. Discussion 
It has been studied recently that Res-analog bearing 3,4-dihydroxy substitution 
(195) is potent apoptotic agent against leukemia. It has also been reported that (196) that 
trihydroxyl Res-analog shows COX-2 inhibition at nanomolar range. According to some 
reports, Res-analog with (197) 3,4-hydroxy substitution in ‘A’ ring results in significant 
apoptotic ability of Res. Based on these observations, in order to enhance cytotoxic 
ability of Res towards breast cancer cells, our collaborative team have synthesized some 
novel analogs of resveratrol (133) where 3,4-dihydroxy substitution on the A ring of Res 
is kept undisturbed while changing the substituents groups at C-4 position on the B ring 
and introduction of Aza linkage in the conjugated system. In the present study, we 
hypothesized that our novel aza-Res analogs; TIMBD and HPIMBD can function as 
effectively as or better than Res as anti-metastatic agents against aggressive and invasive 
phenotypes of breast cancer by prevention of the process of EMT. The results from this 
current study have demonstrated the potency of Res-analogs in down regulation of 
mesenchymal molecular markers along with restoration of epithelial markers in human 
metastatic breast cancer MDA-MB-231 cells. Our findings show that TIMBD and 
HPIMBD are better than Res in restoring epithelial marker E-cadherin expression. The 
mechanism of up-regulation of E-cadherin by Res-analogs involves suppression of snail, 
slug and Zeb1 expressions (Figure 38). In order to dissect out the signaling mechanism 
involved in E-cadherin down regulation, we aimed to examine β-catenin pathway, which 
is frequently associated with negatively controlling the expression of E-cadherin (198). β-
Catenin plays very important role in cell-cell adhesion by interacting with the 
cytoplasmic domain of E-cadherin and activation of this protein leads to up-regulation of 
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canonical Wnt/β-catenin pathway (199, 200). Overexpression and mutations of β-catenin 
are associated with various human cancers including metastatic breast cancer (201). Since 
we found increased E-cadherin expression by Res-analogs, we hypothesized that these 
analogs could prevent the EMT program by targeting Wnt/β-catenin signaling. The 
results from this study have shown that our novel Res-analogs TIMBD and HPIMBD 
down-regulate the expression of β-catenin (Figure 39 B & 39 C). Furthermore, these 
analogs have been shown to regulate cellular distribution of β-catenin in terms of 
restricting its nuclear migration (Figure 41 A & 41 B). In order to find out if β-catenin 
could regulate the expression of E-cadherin, we knocked down β-catenin in MDA-MB-
231 cells by β-catenin-specific siRNA, and confirmed that β-catenin negatively regulates 
E-cadherin expression (Figure 42 A & 42 B). These results are consistent with our 
findings that our novel analogs up-regulate E-cadherin expression with concomitant 
down-regulation of β-catenin expression in MDA-MB-231 cells. Wnt proteins are known 
to play important role in metastatic cancers (202). Wnt proteins bind to cell surface 
receptors, ultimately resulting in the translocation of -catenin to the nucleus. We 
examined the effects of our novel Res-analogs on the expression of different wnt genes 
like wnt-7b, implicated to drive EMT, and wnt-5a which is known as an epithelial marker 
as well as tumor suppressor. Results from our studies have shown that Res-analogs down-
regulate wnt-7b mRNA expression levels (Figure 39 F & 39 G) in metastatic breast 
cancer cells MDA-MB-231. We also found that Res-analogs significantly up-regulate 
epithelial specific wnt-5a in non-tumorigenic breast epithelial cells, MCF-10A (Figure 40 
A & 40 B). These results support our hypothesis that TIMBD and HPIMBD prevent 
EMT by modulating Wnt/β-catenin pathway.  
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 Increased expression of MMPs is also very important molecular signature of 
EMT which helps in the invasion and metastasis of cancer cells. It has already been 
reported that metastatic breast cancer cells undergoing EMT also express elevated levels 
of MMPs. It has also been studied that invasion and migration of breast cancer cells were 
prevented by blocking expression of MMPs (187). We wanted to investigate the effects 
of our novel Res-analogs in the expression levels of MMPs in MDA-MB-231 cells. 
Treatment of breast cancer cells with TIMBD and HPIMBD resulted in down-regulation 
of MMP3 and MMP9 but not MMP2 protein expression levels. Altogether, our study also 
demonstrated that several MMPs are also regulated by TIMBD and HPIMBD (Figure 
37). 
In conclusion, our results represent the first proof that aza-Res analogs TIMBD 
and HPIMBD significantly prevent the process of EMT and up-regulate molecular 
markers of epithelial phenotype such as E-cadherin. Furthermore, we have demonstrated 
the ability of these analogs to prevent metastatic breast cancer cell migration, 
demonstrated by wound healing assays. Our studies have shown the involvement of 
wnt/ catenin pathway as potential underlying mechanism of EMT inhibition by TIMBD 
and HPIMBD. The findings imply that TIMBD and HPIMBD decrease the invasive and 
metastatic properties of aggressive breast cancer cells and thus may be considered as 
potential therapy to prevent spread of breast cancer. 
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CHAPTER 6 
 
NOVEL RESVERATROL ANALOGS TIMBD AND HPIMBD DEMONSTRATE 
CYTOTOXICITY TOWARDS BREAST CANCER CELLS BY A MECHANISM 
INVOLVING AN EARLY ONSET OF AUTOPHAGY 
 
6.1. Introduction 
Breast cancer is one of the most life-threatening diseases all over the world. It is 
very common in women of the United States and is the leading cause of cancer deaths in 
the United States women (1-3). The routinely used treatments of breast cancer include 
chemotherapy, radiation therapy, surgery etc. But standard cancer chemotherapy has 
major problems of adverse side effects (203-205). These side effects are caused by the 
non-specific targeting of the chemotherapeutic drugs, killing normal cells along with the 
cancer cells (203-205). Based on the hormone receptor status, breast cancer can be of 
major three subtypes; (I) estrogen receptor (ER) and progesterone receptor (PR) positive, 
that can be treated by anti-estrogen therapy (206, 207) (II) human epidermal growth 
factor receptor 2 positive HER-2), that can be treated by anti-HER2 antibodies that would 
block HER-2 function (9); and, (III) triple negative breast cancer (TNBC) cases that 
express neither ER, PR nor HER2 and are difficult to treat (208, 209). In the treatment of 
breast cancer commonly the receptors are targeted (ER, PR, HER-2) (206, 207). Triple 
negative breast cancer account for about 10-20% of all sub types of BC (209) Triple 
negative breast cancer more frequently affects younger patients and is more prevalent in 
African American women (210). Women with TNBC are known to have poor prognosis 
126 
 
than women with other BC subtypes (209). It has been reported that less than 30% of 
women with metastatic TNBC survive more than 5 years (211). Molecular mechanisms 
for the etiology, progression and pathobiology of TNBCs are not clear and this subtype is 
clinically characterized as more aggressive and less responsive to standard treatment 
(211). Significantly less progress has been made to date to effectively target TNBCs. 
Hence, there is a critical need to develop newer drugs with higher potency towards 
inhibiting the growth of TNBCs. Additionally, although a number of drugs have been 
developed to treat breast cancer, frequent toxicity is associated with existing drugs to 
normal cells (205). Therefore, it is equally critical to develop newer drugs that not only 
have higher potency to inhibit the growth of TNBCs but also have with minimal or no 
toxicity towards normal cells. 
In order to overcome the limitations of conventional chemotherapeutic drugs and 
to develop  successful agents targeting TNBC and other types breast cancers, 
pharmacologically active resveratrol analogs have been synthesized in such a way that 
they have better anticancer efficacy and specificity than that of the parent compound, Res 
and they have higher potential to kill breast cancer cells. 
Our newly synthesized Res-analog compounds TIMBD and HPIMBD (133), have 
effectively inhibited the growth of both TNBCs and non-TNBCs with no/minimal 
toxicity towards normal cells. Our results suggest that the mechanism responsible for 
higher potency of TIMBD and HPIMBD towards breast cancer cells is through a 
relatively earlier onset of autophagy via a Notch 2 signaling pathway.  
In this current work we have demonstrated that the mechanism of cytotoxic 
effects of TIMBD and HPIMBD towards breast cancer cells involves an early onset of 
127 
 
autophagy. In our preliminary studies we have found that the IC50 values of TIMBD and 
HPIMBD are of <5 µM for TNBC cell line MDA-MB-468 (derived from African 
American breast cancer patient). Thus, development of TIMBD and HPIMBD as novel 
therapeutic compounds for breast cancer inhibition will also have the advantage of 
inhibiting the most aggressive type of breast cancer. 
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6.2. Results 
6.2.1. Res-analog TIMBD and HPIMBD show higher potency for inhibiting the 
proliferation of TNBC cells compared to non-TNBC cells.  
We have tested newly synthesized Res-analogs for their potential to inhibit 
proliferation of breast cancer cells using MTT assay. In our initial screening, we used 5 
breast cancer cell lines (MCF-7, T47D, MDA-MB-468, MDA-MB-231 and BT20) and 3 
non-neoplastic breast epithelial cell lines (MCF-10A, MCF-10F and HMEC). MCF-7 and 
T47D are non-TNBC whereas MDA-MB-231, MDA-MB-468 & BT20 are TNBC cell 
lines. TIMBD and HPIMBD show better potency (p<0.05) than Res in inhibiting the 
growth of all breast cancer cell lines that we tested (Table 2). Importantly, TIMBD and 
HPIMBD show higher potency for inhibiting the proliferation of TNBC cell lines 
compared to non-TNBC cell lines that we tested (p<0.05, Table 2). These two analogs 
have no detectable effect on the growth of any of the 3 non-neoplastic breast epithelial 
cell lines that we tested upto a dose of 50 µM (table 2). HPIMBD is ~9 times and TIMBD 
is ~5 inhibitory for TNBC cell line MDA-MB-468 compared with non-TNBC cell lines 
MCF-7 or T47D as suggested by their IC50 values. Thus, TIMBD or HPIMBD not only 
inhibit breast cancer cell proliferation, they have a preference towards TNBC cells. 
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6.2.2. TIMBD and HPIMBD show anti-clonogenic activity in breast cancer cells 
better than Res  
About 500 viable MDA-MB-231 cells were seeded in six-well plates and allowed 
to grow for 24 hour in phenol red-free complete media. The cells were then treated with 
or without increasing dosages of Res, TIMBD or HPIMBD ( 5 μl, 10 μl and 25 μl )  for 
72 hour, washed in PBS and incubated for an additional 8 days in complete medium. The 
colonies obtained were washed with PBS and fixed in 10% formalin for 10min and again 
washed twice with PBS followed by staining with crystal violet (0.1% w/v solution in 
10% ethanol). The colonies were counted, photographed and compared with respective 
untreated cells (Figure 45). Each treatment was done in triplicate. 
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Figure 45: Comparison of Res, TIMBD and HPIMBD for anti-clonogenic activity in 
breast cancer cells, MDA-MB-231 shown by colony formation assay. MDA-MB-231 
cells were treated with increasing concentrations of Res, TIMBD or HPIMBD for 24 hour 
and colony formation assays were performed as described in the Materials and methods.  
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6.2.3. TIMBD and HPIMBD inhibit mammosphere formation in breast cancer cells 
better than Res  
Mammosphere formation assay was carried out as described in materials and 
method section. Briefly, 5000 viable T47D cells were seeded in ultra-low attachment 
plates. After 24 hour, cells were treated with 50 μM of Res, HPIMBD and TIMBD and 
were grown specific media. After 7-8 days of incubation, mammospheres were viewed 
under the microscope and photographed. Three replicate wells from a 24-well plate were 
used for each experimental condition. 50 nM of E2 induced mammosphere formation; 50 
μM of TIMBD and HPIMBD significantly inhibited formation of mammospheres; 50 μM 
of Res could not inhibit mammosphere formation (Figure 46).  
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Figure 46: Comparison of Res, TIMBD and HPIMBD for anti-tumorigenic activity in 
breast cancer cells, T47D as shown by mammosphere formation assay. T47D cells were 
treated with 50 µM concentrations of Res, TIMBD or HPIMBD for 24 hour and 
mammosphere / spheroid formation assays were performed as described in the Materials 
and methods.  
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6.2.4. TIMBD and HPIMBD show inhibition of growth of breast cancer cells by 
inducing autophagy. 
Our present studies indicate that TIMBD and HPIMBD increase Beclin-1 and 
LC3II protein expression levels in TNBC cell lines MDA-MB-231, MDA-MB-468 and 
non-TNBC cell line T47D (Figure 48), which support autophagy-mediated inhibition of 
cell growth. MDA-MB-231 cells exposed to TIMBD and HPIMBD displayed double 
membrane cytoplasmic structures known as autophagosomes stained with the FITC-
fluorescent MAP-LC3 antibody (Figure 47 A & 47 B). Beclin-1 expression is reported to 
be low in breast cancers and its over expression is reported to inhibit breast cancer. Thus, 
our current studies indicating increased expression of Beclin-1 by TIMBD (Figure 48 A) 
and HPIMBD (Figure 48 B) show clinical relevance of the potential of these agents in 
inhibition of breast tumors. The mechanism of inhibition by TIMBD or HPIMBD is 
potentially different from the documented apoptotic mechanism of inhibition by Res. Our 
present studies show activation of caspase 3/7 by Res whereas TIMBD or HPIMBD show 
inhibition of caspase 3/7 activity, a known marker of apoptosis (Table 3). TIMBD or 
HPIMBD increase protein expression levels of Beclin-1 and LC3II, known markers of 
autophagy whereas Res has no detectable effect on protein expression levels of these 
proteins (Figure 48 A & 48 B). 
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Figure 47: Representative LC3 immunocytochemistry pictures showing formation of 
autophagosomes by Res-analogs in MDA-MB-231 cells. (A) Cells were treated with 
TIMBD (25 µM) for 12 hour, compared with that of vehicle-treated control or Res-
treated cells. Right, enlarged image showing an autophagosome formed in TIMBD-
treated cell; (B) Cells were treated with HPIMBD (25 µM) for 12 hour, compared with 
that of vehicle-treated control or Res-treated cells. Right, enlarged image showing an 
autophagosome formed in HPIMBD-treated cell. 
(A) 
(B) 
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Table 3: Caspase 3/7 activity in MDA-MB-231 and T47D cells treated with Res, TIMBD 
or HPIMBD (50µM) for 24 hour. Resveratrol showed significant increase in caspase 3/7 
activity in these breast cancer cells suggesting apoptosis-mediated cell death. In contrast, 
TIMBD or HPIMBD showed significant decrease in caspase 3/7 activity which suggests 
these Res-analogs do not mediate apoptotic cell death like that of Res. 
‘*’ indicates p value ≤ 0.05 compared with respective controls. 
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(B) 
(A) 
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Figure 48: Res-analogs, TIMBD and HPIMBD shows induction of autophagy in 
different breast cancer cells. (A) Representative Western blots for Beclin-1 and LC3 in 
MDA-MB-231, MDA-MB-468 and T47D cells treated with Res or TIMBD for 12, 6 and 
24 hour, respectively; and (B)  Representative Western blots for Beclin-1 and LC3 in 
MDA-MB-231, MDA-MB-468 and T47D cells treated with Res or HPIMBD for 12, 6 
and 24 hour, respectively. 
 *p<0.05 compared to vehicle-treated cells. 
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6.2.5. TIMBD or HPIMBD induce autophagy via Notch 2 pathway. 
Our present results demonstrate that TIMBD (Figure 50) and HPIMBD (Figure 
51) increase Notch 2 protein levels with induction at an earlier time point in TNBC cell 
line MDA-MB-231 (6 hour) compared to non-TNBC cell line T47D (12 hour). 
Concomitant with an increase in Notch 2 protein levels, there is a corresponding increase 
in Beclin-1 protein levels (Figure 50 & Figure 51). Protein expression levels of Beclin-1 
and Notch 2 remain high in TNBC cell line MDA-MB-231 for upto 12 hours. Silencing 
of Notch 2 using siRNA to Notch 2, results in decreased expression of Beclin-1 (Figure 
49). These results suggest that Notch 2 may play an important role in TIMBD and 
HPIMBD-mediated induction of autophagy. 
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Figure 49: Notch 2 positively controls the expression of autophagy-related protein 
Beclin-1. Representative western blot showing decreased Beclin-1 protein expression in 
si Notch 2 transfected MCF-10A cells. 
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Figure 50: Res-analog TIMBD induces autophagy via Notch 2 pathway. Representative 
western blots showing Notch 2 and Beclin-1 protein expressions in MDA-MB-231 and 
T47D cells, following TIMBD (50 µM) treatment. 
 
 
 
 
 
 
 
Figure 51: Res-analog HPIMBD induce autophagy via Notch 2 pathway. Representative 
western blots showing Notch 2 and Beclin-1 protein expressions in MDA-MB-231 and 
T47D cells, following HPIMBD (50 µM) treatment. 
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6.3. Discussion 
Triple negative breast cancer (TNBC) comprises of 15-20% of all breast cancers 
and is the most aggressive and invasive subtype of breast cancer.  In general, for 
treatment of breast cancers, hormonal receptor status is essential to be determined in 
order to target cancer cells. Treatment for breast cancer largely depends on the presence 
of ER, PR or HER-2 receptors in the cancer cells. But TNBC is that sub type of breast 
cancer that lacks positive hormone receptor status and that is why chemotherapeutic 
treatment targeting hormonal receptors and molecular markers all are ineffective to treat 
TNBC.  Although Chemotherapy is still the major strategy for treatment of TNBC, 
reoccurrence of the disease is a challenging drawback. Therefore, it is very important to 
develop novel drugs with higher potency towards inhibiting the growth of TNBCs. The 
pharmacological agents that have been developed for treatment of breast cancer are found 
to exert toxicity to normal cells (203-205). Therefore, it is equally important to develop 
novel therapeutic agents that should have specificity towards inhibiting growth of TNBCs 
having minimal or no toxicity towards normal cells. 
Nature has endowed us with a variety of non-synthetic natural compounds with 
unique medicinal values. One of the hugely studied naturally occurring plant derived 
phyto-estrogen is namely resveratrol (Res), well studied for its medicinal properties. It is 
found in various vegetables, nuts, fruits including grapes and red wine. Res have been 
well explored for its plethora of medicinal properties in treatment of cancer and a wide 
range of other diseases (90-92). Resveratrol mediates its anticancer activity by inducing 
apoptosis in cancer cells via modulating various signal transduction pathways and 
targeting different transcription factors responsible for uncontrolled growth of cancer 
142 
 
cells (115-119). Not only limited to in vitro studies, Res has also been successfully shown 
to reduce growth of primary tumor xenografts in animal model (120).  
We have recently synthesized some novel resveratrol analogs by maintaining 3,4-
dihydroxy substitution on the A ring while varying the substituents at C-4 position on the 
B ring along with inclusion of Aza functionality in the conjugated system (133). The 
analogs synthesized were named as TIMBD and HPIMBD (133), have extensively 
studied for their anti proliferative properties on breast cancer cells. TIMBD and HPIMBD 
have shown to inhibit breast cancer cell proliferation effectively and successfully with no 
or least toxicity towards normal breast epithelial cells.  
In this current work we have shown the potency of TIMBD and HPIMBD in 
inhibiting the proliferation of breast cancer cells with a preference towards TNBC cells 
(Table 2). We found the IC50 of TIMBD and HPIMBD of <5 µM in the TNBC cell line 
MDA-MB-468 (Table 2). It is reported that IC50 value of <5 µM is well within the 
acceptable range for evaluation of a drug for efficacy and safety in a clinical setting (139-
140). Thus, in this current study we aimed at developing TIMBD and HPIMBD as novel 
therapeutic compounds for treatment of breast cancer with minimal or no toxicity towards 
normal breast epithelial cells (Table 2). To further delineate the mechanism responsible 
for higher potency of TIMBD and HPIMBD towards breast cancer cells, we found is 
through a relatively earlier onset of autophagy (Figure 48) via a Notch 2 signaling 
pathway (Figure 49-51). 
There are two major types of cell death processes cumulatively called as 
Programmed cell death, apoptosis (Type-I) and autophagy (Type-II) (212, 213). 
Autophagy, is defined as a cellular process that mediates degradation of cellular 
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components through formation of autolysosomes which are formed by fusion of 
autophagosomes with lysosomal vesicles (214). Autophagy is reported to play important 
role in cancer and may be defective in tumour cells (215). It is evident from literature that 
autophagic cell death is an alternative pathway to target cancer cells and 
chemotherapeutic agents often induce this pathway where apoptotic cascades are inactive 
(216). According to these scientific evidences it might be said that molecular players of 
autophagy are very important to prevent the process of carcinogenesis. In the current 
study, we demonstrated that the novel resveratrol analogs TIMBD and HPIMBD induce 
the process of autophagic cell death in breast cancer cell lines (Figures 47 & Figure 48). 
We have used human immortalized estrogen receptor positive breast cancer cell line, 
T47D and TNBC cell lines MDA-MB-231 and MDA-MB-468 for our studies. MDA-
MB-231 cells exposed to TIMBD and HPIMBD displayed double membrane cytoplasmic 
structures known as autophagosomes staining with the FITC-fluorescent MAP-LC3 
antibody (Figure 47 A & 47 B). To confirm autophagic protein activation by TIMBD and 
HPIMBD, we studied induction of autophagy specific protein Beclin 1 (217) and 
conversion of the soluble form of LC3 which is found on the autophagosome membrane 
(LC3-I) to lipidated and autophagosome-associated form (LC3-II) by western blotting 
(Fig. 3B). Beclin 1 protein expression is reported to be lower in breast cancer cells and its 
poor expression is correlated with development of breast cancer (217). In our current 
study we have demonstrated that TIMBD and HPIMBD induce Beclin 1 in TNBC as well 
as non-TNBCs, with an early onset in the later cell lines (Figure 48 A & 48 B). To make 
sure that our novel Res-analog induces cancer cell death by autophagy and not by type-I 
cell death apoptosis, we performed caspase3/7 activity assay and TIMBD and HPIMBD 
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showed down regulation of caspase3/7 activity (Table 3). These results clearly suggest 
that TIMBD and HPIMBD kill cancer cells by inducing autophagy and not by apoptosis 
like its parent compound, Res (115). 
Notch signaling is a very important cell signaling pathway involved in 
carcinogenesis development and is considered as tumor-suppressor (218). There are four 
isoforms of Notch heterodimeric transmembrane receptors (Notch 1 through Notch 4) 
expressed in Humans (219). It is known that the different Notch receptors display 
diversity in their functions (218). In breast cancer, there is strong evidence that Notch 1 
and Notch 4 are oncogenic, whereas Notch 2 may play a tumor-suppressive role (218, 
220). Biologically, there is evidence that Notch 2 has opposite effects compared with 
Notch 1 in human breast cancer (220). 
In this study, we show that Notch 2 signaling is involved in potentiating TIMBD and 
HPIMBD for their autophagic activities towards breast cancer cells (Figure 50 & Figure 
51). This study may be very important to discover novel pharmacological interventions 
for treatment of breast cancer including very aggressive TNBCs. 
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CHAPTER 7 
 
ANIMAL STUDIES 
 
7.1. HPIMBD inhibits tumor development in vivo in an orthotopic mouse xenograft 
model.  
We have done some preliminary experiments with laboratory animals to study the 
efficacy of HPIMBD in inhibition of tumor growth. As a model system for our studies we 
have used an orthotopic nude mouse xenograft model of breast cancer. In our pilot 
studies with animals, nude mice (n=2) were injected with 1x106 MDA-MB-231 breast 
cancer cells in the mammary fat pad. All mice were given free access to phytoestrogen-
free food and water. Animals were injected with HPIMBD (in DMSO) intraperitonially at 
a dose of 50mg/kg body weight, two days before injection with MDA-MB-231 cells. We 
repeated this dose on every 2nd day, for 6 weeks. In our experience, tumors are usually 
generated within 2-3 weeks of cells’ injection into nude mice. According to our 
observations, no visible tumors developed in mice injected with MDA-MB-231 cells and 
HPIMBD, while tumors developed in control nude mice injected with MDA-MB-231 
cells and DMSO (Figure 52). These results imply that HPIMBD has the potential to 
inhibit breast tumor growth in in vivo systems. Nevertheless, these data are preliminary 
and need to be confirmed using more mice based on power analyses (n=15) to provide 
statistically supportive results. 
We performed the same experiments using xenograft with estrogen receptor (ER) 
positive cells T47D. In our preliminary feasibility experiments to check the efficacy of 
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HPIMBD in inhibition of E2-dependent tumor growth, nude mice (n=2) were implanted 
with E2 two days before injection with 1x106 T47D cells in mammary fat pad. On the day 
of implantation of E2, mice were also injected mice subcutaneously with HPIMBD 
dissolved in DMSO at 50mg/kg body weight. This dose was repeated on every alternate 
day for 4 weeks. We did not observe any visible tumors developed in mice injected with 
T47D and HPIMBD while tumors developed in control mice treated with T47D cells 
alone (Figure 53). Our results imply that HPIMBD has the potential to inhibit E2-
dependent tumor growth. 
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Figure 52: HPIMBD inhibits tumor development in vivo in an orthotopic mouse 
xenograft model. (A) Development of visible tumors near nipples of a nude mouse 
injected with MDA-MB-231 cells; and (B) No visible tumors in a nude mouse treated 
simultaneously with HPIMBD. C= tumor size excised from MDA-MB-231 injected 
mouse.  
 
 
 
 
 
Figure 53: HPIMBD inhibits tumor development in vivo in an orthotopic mouse 
xenograft model. (A) E2-pellet implanted; (B) Development of visible tumor near nipples 
of a nude mouse injected with T47D cells; and (C) No visible tumors in a nude mouse 
treated simultaneously with HPIMBD.  
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SUMMERY & FUTURE PERSPECTIVE 
 
Cancers can be categorized as preventable diseases as onset of this disease is 
largely connected to lifestyle and daily food habits. Cancer occurrence thus can be 
significantly reduced by maintaining a healthy diet. It has largely been suggested that 
consumption of plant-based diets which contain large amount of antioxidants, can be 
protective against carcinogenic insult. It has also been suggested that by reducing intake 
of red meats, fried, high salt and high sugar-rich foods cancer can be avoided. It is thus 
very clear that regular consumption of various plant-derived chemicals or phytochemicals 
found in a variety of fruits, nuts, vegetables and grains will significantly reduce the risk 
of cancer occurrence. Long-term consumption of plant-derived foods rich in antioxidants 
like VC and Res is well known to exert significant health benefits. In contrast with 
conventional synthetic cancer drugs, natural chemopreventive compounds have been 
found to be more beneficial in specifically inhibiting cancer cell growth with low 
cytotoxic effect to the normal cells. Although modern chemotherapeutic drugs have 
resulted in significant survival of breast cancer patients but these drugs have limitations 
in terms of significant side effects and development of resistance. For example, 
anthracyclines, cyclophosphamide, taxanes, tamoxifen etc which are routinely used in the 
drug regimen of breast cancer patients have significant adverse side effects due to their 
toxic effects on normal cells. Not only this, but these chemotherapeutic agents are also 
associated with the development of drug resistance. All these reasons result in withdrawal 
of chemotherapeutic treatments in >20% of women.  
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According to the epidemiological studies, the rates of breast cancer incidence are 
lower among Asians which is suggestive of the fact that Asian women consume food 
which help them to prevent breast cancer onset. Studies from various in vitro experiments 
have shown beneficial effects of naturally occurring antioxidants like VC or Res in breast 
cancer chemoprevention. But in vivo studies have demonstrated the limitations of these 
natural phytochemicals which holds us back to use them in clinical settings. Lower 
efficacy is an issue with most of the phytochemicals including resveratrol which limit the 
achievement of their physiologically effective doses in the in vivo system. 
It is thus very clear that in order to make natural phytochemicals effective in in 
vivo systems and use them in clinical settings chemical modifications are needed to make 
these natural compounds very stable as well as selective. We have synthesized Res 
analogs, namely TIMBD and HPIMBD to improve the efficacy of Res. We have 
extensively studied these analogs for their anti-proliferative properties on breast cancer 
cells. Our results suggest that TIMBD and HPIMBD specifically inhibit the proliferation 
of human breast cancer cells. Additionally, we observed that these novel analogs had no 
cytotoxic effects on the growth of human non-neoplastic breast epithelial cells.  These 
results with TIMBD and HPIMBD were very promising and encouraging to develop 
them as potential anti breast cancer agents. We also delineated the possible molecular 
mechanisms of chemoprevention by these analogs.  
Our aim is to develop novel res-analogs TIMBD and HPIMBD as potential 
therapeutic agents that can be used to selectively inhibit development of breast cancer 
with no or minimal toxicity towards normal cells of the patient. To fulfill our goal, we 
have extensively studied these two compounds for their ability to target different genes 
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and proteins and various signaling pathways. We have observed that TIMBD and 
HPIMBD are very potent to scavenge reactive oxygen species (ROS) production and 
provide antioxidant defense to normal breast epithelial cells by reducing ROS-induced 
oxidative DNA damage. When we started looking in to the possible molecular 
mechanism underlying the antioxidant properties of TIMBD and HPIMBD, we observed 
that these two analogs are very potent in inducing cellular phase-II detoxifying genes like 
SOD3 and NQO1. We have then demonstrated that TIMBD and HPIMBD up regulate 
cellular Phase-II detoxifying system by up regulation of transcription factor Nrf2, the 
master regular of antioxidant defense system. In addition to Nrf2, we studied other 
members of CNC-bZip family of proteins which are known to play important roles in 
antioxidant defense in mammalian cells, Nrf1 and Nrf3. We have studied Nrf1 and Nrf3 
for their specific roles in hormonal breast cancer, in particular, E2-dependant breast 
cancer and the effects of TIMBD and HPIMBD in the regulation of these transcription 
factors. Results from our extensive studies have suggested that TIMBD and HPIMBD 
confer antioxidant defense to the normal breast epithelial cells and protect them from 
carcinogenic insult by modulating mRNA and protein expression levels of Nrf1, Nrf2 and 
Nrf3. Here, in this present study, we have presented evidence that our novel Res-analogs 
TIMBD and HPIMBD are very effective antioxidant agents. These analogs thus can 
provide defense to the normal breast epithelial cells from carcinogenic insult by reducing 
ROS and oxidative DNA-damage which are frequently associated with onset of 
carcinogenic process. Based on the results that we have obtained it can be concluded that 
since TIMBD and HPIMBD specifically kill human breast cancer cells without having 
toxicity towards normal breast epithelial cells, they could be used as promising 
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chemotherapeutic agents for the treatment of breast cancer patients. In this way we may 
avoid the adverse side effects of otherwise used conventional chemotherapeutic agents in 
breast cancer. With our observations of novel res-analogs having potent antioxidant 
properties, we could use them for prevention of breast cancer. Whether the effects of 
TIMBD and HPIMBD will show promising results for prevention as well as treatment of 
breast cancer in the clinical settings, it is still a challenging question one could ask. It will 
be imperative to do animal experiment studies using significant number of model animals 
receiving TIMBD and HPIMBD in their daily diets, to prove these drugs efficacy as anti-
tumor and chemopreventive agents. Although we have developed Nude mouse orthotopic 
model of breast cancer in our laboratory and used them to study tumor prevention as well 
as tumor inhibition by administrating TIMBD or HPIMBD intraperitonially, there were 
not sufficient number of animals used to make a significant conclusion. But based on our 
pilot animal studies we observed a significant regression of breast tumor in these after 
administration of TIMBD or HPIMBD. We also observed that tumor development could 
be prevented in these experimental animals by giving them TIMBD or HPIMBD prior to 
implantation of breast cancer cell xenografts. These pilot animal studies have given 
promising results based on which we can design animal experiments in a larger scale to 
provide evidence that TIMBD and HPIMBD are promising agents for treatment as well 
as prevention of breast cancer.  
Reoccurrence and metastasis are frequently associated with breast cancer. Breast 
cancer metastasis can become worst; resulting in migration of the cancer cells in to the 
other organs of the body like lungs and bones and ultimately can cause death. Treatment 
for metastatic breast cancer includes chemotherapy, radiation therapy, surgery etc. At 
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present, Treatment of metastatic breast cancer is an active and dynamic field of research. 
Various novel anti-metastatic drugs are being developed to particularly treat metastatic 
breast cancers. In order to develop TIMBD and HPIMBD as potential anti-tumor agents, 
we aimed to examine the anti-metastatatic properties of these novel analogs of Res. Our 
results have presented the first proof evidence that TIMBD and HPIMBD can 
significantly prevent the molecular process of epithelial-mesenchymal transition (EMT) 
and breast cancer cell metastasis in in vitro system. Next we have dissected out the 
possible molecular mechanisms underlying anti-metastatic activities of TIMBD and 
HPIMBD in breast cancer. We have observed that these analogs can significantly down-
regulate matrix metalloproteases (MMPs) which are implicated in driving cell metastasis; 
and by up regulating molecular markers of epithelial phenotype such as E-cadherin. 
Furthermore, we have demonstated the ability of these analogs to prevent metastatic 
breast cancer cell migration. Furthermore, our studies have shown that suppression of 
wnt/ catenin signaling pathway could be a potential underlying mechanism of EMT 
inhibition by our Res-analogs. Taken together, these findings suggest that TIMBD and 
HPIMBD can act as potential anti-metastatic agents and thus can be used successfully to 
decrease the invasive and metastatic properties of aggressive breast cancer cells.  
In the 6th chapter we have discussed about the possible mechanisms by which our 
novel res analogs target breast cancer cells and inhibit their growth. We found TIMBD 
and HPIMBD induced Beclin-1 and LC3II which suggest autophagy mediated inhibition 
of cell growth. Beclin-1 is known to be suppressed in breast cancers and it’s over 
expression is reported to inhibit breast cancer. Results from our studies demonstrate that 
Res-analogs TIMBD and HPIMBD are better than Res in inhibiting specifically breast 
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cancer cell growth and shows higher potency for inhibiting the growth of triple negative 
breast cancer cells by inducing autophagy with an earlier onset for triple negative breast 
cancer cells. Therefore, TIMBD and HPIMBD may be better chemotherapeutic agent 
than Res against breast cancer and more specifically against triple negative breast cancer 
cell growth.   
In conclusion, it can be inferred that our newly synthesized Res-analogs TIMBD 
and HPIMBD have significant potential to inhibit growth of breast cancer cells without 
having any toxicity towards normal cells and they can be developed as potential 
chemotherapeutic agents for breast cancer. In future studies, we will investigate the 
pharmacokinetics and pharmacodynamics parameters of TIMBD and HPIMBD and test 
them in clinical settings. Our ultimate and long term goal is to develop TIMBD and 
HPIMBD as promising chemotherapeutic agents in breast cancer and to protect 
individuals from breast-cancer related deaths.  
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Figure 54: Resveratrol analogs: potential mechanism of chemoprevention in breast 
cancer 
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